

1230982

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

September 27, 2004

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.

APPLICATION NUMBER: 60/499,317

FILING DATE: August 29, 2003

RELATED PCT APPLICATION NUMBER: PCT/US04/28240

Best Available Copy

Certified by



Jon W Dudas

Acting Under Secretary of Commerce
for Intellectual Property
and Acting Director of the U.S.
Patent and Trademark Office



PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c).

Express Mail Label No. EV 341 016 768 US


INVENTOR(S)		Residence (City and either State or Foreign Country)
Given Name (first and middle [if any])	Family Name or Surname	
Rolf	Jessberger	White Plains, NY
Ekaterina	Revenkova	Fort Lee, NJ
Additional inventors are being named on the _____ separately numbered sheets attached hereto		
TITLE OF THE INVENTION (500 characters max)		
METHODS FOR IDENTIFYING, TREATING, AND INDUCING INFERTILITY USING SMC1β		
Direct all correspondence to: CORRESPONDENCE ADDRESS		
<input type="checkbox"/> Customer Number: _____		
OR		
<input checked="" type="checkbox"/> Firm or Individual Name	Lynn L. Janulis, Ph.D. MARSHALL, GERSTEIN & BORUN LLP	
Address	233 S. Wacker Drive, Suite 6300 Sears Tower	
City	Chicago	State IL Zip 60606
Country	USA	Telephone 312-474-6300 Fax 312-474-0448
ENCLOSED APPLICATION PARTS (check all that apply)		
<input checked="" type="checkbox"/> Specification Number of Pages	84	<input type="checkbox"/> CD(s), Number _____
<input type="checkbox"/> Drawing(s) Number of Sheets	_____	<input type="checkbox"/> Other _____
<input type="checkbox"/> Application Data Sheet. See 37 CFR 1.76 (specify): _____		
METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT		
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27.		FILING FEE AMOUNT (\$) \$80.00
<input checked="" type="checkbox"/> A check or money order is enclosed to cover the filing fees.		
<input checked="" type="checkbox"/> The Director is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number: 13-2855		
<input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.		
The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.		
<input checked="" type="checkbox"/> No <input type="checkbox"/> Yes, the name of the U.S. Government agency and the Government contract number are: _____		

[Page 1 of 1]

Respectfully submitted,

Date August 29, 2003

SIGNATURE
TYPED OR
PRINTED NAME
TELEPHONE


Lynn L. Janulis, Ph.D.

1-312-474-6300

REGISTRATION NO.
(if appropriate)


53,066

Docket Number:

29636/39363

USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT

22389 U.S. PTO
60/499317



16563 U.S. PTO
08/29/03

PTO/SB/17 (10-02)

Approved for use through 10/31/2002. OMB 0651-0032

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

FEE TRANSMITTAL for FY 2003

Patent fees are subject to annual revision.

☒ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$) 80.00

Complete if Known

Application Number	Not Yet Assigned
Filing Date	August 29, 2003 (herewith)
First Named Inventor	Rolf Jessberger
Examiner Name	Not Yet Assigned
Group Art Unit	Not Yet Assigned
Attorney Docket No.	29636/39363

METHOD OF PAYMENT (check all that apply)

☒ Check ☐ Credit Card ☐ Money Order ☐ Other ☐ None

☒ Deposit Account

Deposit Account Number 13-2855

Deposit Account Name MARSHALL, GERSTEIN & BORUN LLP

The Commissioner is hereby authorized to: (check all that apply)

☐ Charge fee(s) indicated below ☒ Credit any overpayments

☒ Charge any additional fee(s) during the pendency of this application

☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

FEE CALCULATION

1. BASIC FILING FEE

Large Entity	Small Entity	Fee Code	Fee (\$)	Fee Description	Fee Paid
		1001	750	Utility filing fee	
		1002	330	Design filing fee	
		1003	520	Plant filing fee	
		1004	750	Reissue filing fee	
		1005	160	Provisional filing fee	80.00
SUBTOTAL (1)					80.00

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

Total Claims	Extra Claims	Fee from below	Fee Paid
Independent Claims			
Multiple Dependent			

Large Entity	Small Entity	Fee Code	Fee (\$)	Fee Description	Fee Paid
		1202	18	Claims in excess of 20	
		1201	84	Independent claims in excess of 3	
		1203	280	Multiple dependent claim, if not paid	
		1204	84	** Reissue independent claims over original patent	
		1205	18	** Reissue claims in excess of 20 and over original patent	
SUBTOTAL (2)					0.00

**or number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Entity	Small Entity	Fee Code	Fee (\$)	Fee Description	Fee Paid
		1051	130	Surcharge - late filing fee or oath	
		1052	50	Surcharge - late provisional filing fee or cover sheet	
		1053	130	Non-English specification	
		1812	2,520	For filing a request for ex parte reexamination	
		1804	920*	Requesting publication of SIR prior to Examiner action	
		1805	1,840*	Requesting publication of SIR after Examiner action	
		1251	110	Extension for reply within first month	
		1252	410	Extension for reply within second month	
		1253	930	Extension for reply within third month	
		1254	1,450	Extension for reply within fourth month	
		1255	1,970	Extension for reply within fifth month	
		1401	320	Notice of Appeal	
		1402	320	Filing a brief in support of an appeal	
		1403	280	Request for oral hearing	
		1451	1,510	Petition to institute a public use proceeding	
		1452	110	Petition to revive - unavoidable	
		1453	1,300	Petition to revive - unintentional	
		1501	1,300	Utility issue fee (or reissue)	
		1502	470	Design issue fee	
		1503	630	Plant issue fee	
		1460	130	Petitions to the Commissioner	
		1807	50	Processing fee under 37 CFR 1.17(q)	
		1808	180	Submission of Information Disclosure Stmt	
		8021	40	Recording each patent assignment per property (times number of properties)	
		1809	750	Filing a submission after final rejection (37 CFR 1.129(a))	
		1810	750	For each additional invention to be examined (37 CFR 1.129(b))	
		1801	750	Request for Continued Examination (RCE)	
		1802	900	Request for expedited examination of a design application	

Other fee (specify)

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$) 0.00

SUBMITTED BY

Name (Print/Type) Lynn L. Janulis, Ph.D.

Registration No. (Attorney/Agent)

53,066

Complete (if applicable)

Telephone 312-474-6300

Signature

Lynn L. Janulis

Date

August 29, 2003

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 341 016 768 US, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: August 29, 2003

Signature:

Richard Zimmermann


(Richard Zimmermann)

<h1 style="text-align: center;">TRANSMITTAL FORM</h1> <p style="text-align: center;">(to be used for all correspondence after initial filing)</p>		Application Number	Not Yet Assigned
		Filing Date	August 29, 2003 (herewith)
		First Named Inventor	Rolf Jessberger
		Art Unit	Not Yet Assigned
		Examiner Name	Not Yet Assigned
Total Number of Pages in This Submission	88	Attorney Docket Number	29636/39363

ENCLOSURES (Check all that apply)

<input checked="" type="checkbox"/> Fee Transmittal Form <input checked="" type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Return receipt postcard
Remarks		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual name	MARSHALL, GERSTEIN & BORUN LLP Lynn L. Janulis, Ph.D. - 53,066
Signature	
Date	August 29, 2003

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV 341 016 768 US, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: August 29, 2003

Signature:  (Richard Zimmermann)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
APPLICATION FOR UNITED STATES LETTERS PATENT

PROVISIONAL APPLICATION COVER SHEET FOR APPLICATION OF TITLE:

**METHODS FOR IDENTIFYING, TREATING, AND
INDUCING INFERTILITY USING SMC1 β**

BY INVENTORS:

Rolf Jessberger, Ph.D.

190 Saxon Woods Rd.
White Plains, NY 10605
United States of America
Citizenship: Germany

Ekaterina Revenkova

2419 Leighton St.
Fort Lee, NJ 07024
United States of America
Citizenship: Russia

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☒ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.

Methods for Identifying, Treating, and Inducing Infertility Using SMC1 β

FIELD OF THE INVENTION

The present invention generally relates to reproductive fertility and, more particularly, to methods and compositions that can be used in male and female contraception and fertility.

BACKGROUND OF THE INVENTION

A novel protein of the structural maintenance of chromosomes (SMC) family of proteins, SMC1 β , was recently discovered (Revenkova *et al.*, *Mol. Cell. Biol.* 21: 6984-6998, 2001). SMC proteins are generally involved in chromosome dynamics, for example, in chromosome condensation during mitosis or in the alignment of the newly synthesized DNA molecules after DNA replication ("sister chromatid cohesion") (reviewed in Jessberger, *Nature Reviews, Mol. Cell. Biol.* 3: 767-778, 2002). SMC proteins are evolutionary highly conserved and found in prokaryotes, as well as, in all eukaryotes examined, including humans. SMC proteins show a characteristic protein design with two globular domains at each terminus separated by an extended coiled-coil domain that at its center bears a third globular domain, the flexible hinge region. The terminal globular domains carry specific functional motifs such as the Walker A box, Walker B box (both involved in NTP binding and hydrolysis), a conserved FSKY motif, and the signature motif LSGG (see Jessberger, *supra*, 2002).

SMC1 β was isolated from mammalian (bovine, mouse, rat) testis nuclear extracts and turned out to be the first, and so far only, mammalian meiosis-specific SMC protein. SMC1 β does not exist in prokaryotes, yeast, or other lower eukaryotes including the nematode *C. elegans*. SMC1 β is similar to the canonical SMC1, but contains specific differences such as a unique C-terminal peptide sequence. The overall identity to SMC1 is limited to 45 - 79 %, depending on the individual domain. Thus, it provides sufficient uniqueness to allow development of specific reagents such as small compounds or antibodies. The specificity of SMC1 β for meiotic cells was demonstrated in several tissues by several methods that include Northern blot analyses of RNA, Western blot analyses of protein extracts using antibodies specific for SMC1 β , immunofluorescence studies on tissue sections

and on chromosome spreads, and by immunoprecipitation from various extracts (Revenkova *et al.*, *supra*, 2001; Eijpe *et al.*, *J. Cell Biol.*, 160: 657-670, 2003). SMC1 β was found to be exclusively expressed in meiotic cells, starting with the leptotene phase of meiosis I, and continues to be expressed until metaphase of meiosis II. In meiotic cells, SMC1 β localizes to the core of meiotic chromosomes.

A role for SMC1 β in sister chromatid cohesion of meiotic chromosomes throughout meiosis I and meiosis II has also been revealed. Evidence indicates that SMC1 β , within a multiprotein complex, is acting as the "clamp" that holds sister chromatids together during meiosis (Revenkova *et al.*, 2001). This phenomenon is absolutely required for meiotic progression and thus for spermatogenesis and oogenesis. Consequently, the absence of SMC1 β is thought to have a deleterious effect on spermatogenesis and/or oogenesis. Methods and compositions for exploiting these findings are discussed in further detail in the present specification.

SUMMARY OF THE INVENTION

The present invention relates to a structural maintenance of chromosome protein, SMC1 β , and uses thereof. More specifically, the present invention provides methods for inducing or inhibiting fertility, comprising administering to an animal an effective therapeutic amount or an effective contraceptive amount, of an agent that either inhibits or induces SMC1 β expression or activity.

In one aspect, therefore, the present invention provides a method for inducing infertility in an animal. Such a method generally would comprise administering to the animal an effective contraceptive amount of an agent that inhibits SMC1 β expression or activity. The term "inhibits SMC1 β expression or activity" means decreases, lowers, downregulates, or otherwise decreases the endogenous effects of SMC1 β . In certain embodiments, the method may further comprise restoring fertility to the animal by ceasing administration of the agent that inhibits SMC1 β expression or activity. In another embodiment, the infertility may be caused by blocking gametogenesis, such as spermatogenesis in the male and/or oogenesis in the female. In a further embodiment, spermatogenesis and/or oogenesis is blocked by inhibiting meiosis in developing germ cells. In a certain embodiment, the meiosis is inhibited at prophase of meiosis I or later. The present invention also contemplates an agent that

inhibits SMC1 β expression or activity that is selected from the group consisting of: a nucleic acid construct, a small molecule antagonist of SMC1 β , a peptidomimetic antagonist of SMC1 β , and an anti-SMC1 β antibody. In another embodiment, the agent is administered in a composition comprising a pharmaceutically acceptable carrier. In a further embodiment, the pharmaceutically acceptable carrier is an adjuvant, solubilizer, stabilizer, diluent, anti-oxidant, liposome, micelle, or patch. In a preferred embodiment of the invention, the animal is human.

In another aspect, the present invention relates a method of treating infertility in an animal. Such a method generally would comprise administering to the animal an effective therapeutic amount of exogenous SMC1 β or an agent that induces SMC1 β expression or activity. The term "induces SMC1 β expression or activity" means increases, augments, upregulates, or otherwise increases the endogenous effects of SMC1 β . In certain embodiments, the infertility is treated by stimulating gametogenesis, such as spermatogenesis in the male or oogenesis in the female. In other embodiments, the spermatogenesis or oogenesis is stimulated by inducing meiosis in developing germ cells. In a certain embodiment, the meiosis is induced at or after prophase of meiosis I. The present invention also contemplates an agent that is selected from the group consisting of: a nucleic acid construct that encodes the SMC1 β polypeptide, an SMC1 β polypeptide, a small molecule agonist of SMC1 β , and a peptidomimetic agonist of SMC1 β . In another embodiment, the agent is administered in a composition comprising a pharmaceutically acceptable carrier. In a further embodiment, the pharmaceutically acceptable carrier is an adjuvant, solubilizer, stabilizer, diluent, anti-oxidant, liposome, micelle, or patch. In another embodiment, the agent is administered orally, parenterally, topically, or transdermally. In one embodiment, the administration is to the testis. In a certain embodiment, this administration to the testis is by a route selected from the group consisting of: injection, implantation, and transdermal application. In another embodiment, the administration is to the ovary. In a further embodiment, the administration to the ovary is by injection or implantation. In a preferred embodiment of the invention, the animal is human.

The present invention also contemplates a method of inhibiting meiosis in germ cells. Such a method generally would comprise inhibiting the expression or activity of SMC1 β in the cells. In one embodiment, the germ cells are spermatocytes. In another embodiment, the germ cells are oocytes. In a further embodiment, meiosis is inhibited at prophase of meiosis I. In certain embodiments, the cells are located either in vitro or in vivo.

In another embodiment, cells are located in an animal subject. Preferably, the subject is human. In a further embodiment, the method comprises contacting the cells with an agent that reduces the expression or activity of SMC1 β . In one embodiment, the agent is a nucleic acid construct. In another embodiment, the agent is a small molecule antagonist of SMC1 β .

5 In a further embodiment of the invention, the agent is a peptidomimetic antagonist of SMC1 β . In a different embodiment, the agent is an anti-SMC1 β antibody. In a further aspect, the agent is administered in a composition comprising a pharmaceutically acceptable carrier. Preferably, the pharmaceutically acceptable carrier is an adjuvant, solubilizer, stabilizer, diluent, anti-oxidant, liposome, micelle, or patch.

10 The present invention further contemplates a method of inducing meiosis in germ cells. Such a method generally comprises inducing the expression or activity of SMC1 β in the cells. In one embodiment, the germ cells are spermatocytes. In another embodiment, the germ cells are oocytes. In a certain embodiment, meiosis is induced at prophase of meiosis I or later. In further embodiments, the cells are located either in vitro or in vivo. In
15 another embodiment, cells are located in an animal subject. Preferably, the subject is human. In a further embodiment, the method comprises contacting the cells with exogenous SMC1 β or an agent that induces the expression or activity of SMC1 β . In one embodiment, the agent is a nucleic acid construct that encodes the SMC1 β polypeptide. In another embodiment, the agent is the SMC1 β polypeptide. In a further embodiment of the invention, the agent is a
20 small molecule agonist of SMC1 β . In a different embodiment, the agent is agent is a peptidomimetic agonist of SMC1 β . In a further aspect, the agent is administered in a composition comprising a pharmaceutically acceptable carrier. Preferably, the pharmaceutically acceptable carrier is an adjuvant, solubilizer, stabilizer, diluent, anti-oxidant, liposome, micelle, or patch.

25 The invention also contemplates a method for treating a disorder in an animal resulting from decreased levels of SMC1 β polypeptide. Such a method generally comprises administering to an animal the SMC1 β polypeptide or the nucleic acid encoding the polypeptide of SMC1 β to the animal.

In a different aspect, the invention contemplates a method of diagnosing a
30 disorder or susceptibility to a disorder in an animal caused by or resulting from abnormal levels of SMC1 β polypeptide. This method generally comprises: a) determining the presence or amount of expression or activity of the SMC1 β polypeptide or a nucleic acid encoding the

polypeptide of SMC1 β in a sample; and b) comparing the level of SMC1 β polypeptide or the nucleic acid encoding the polypeptide of SMC1 β in a biological, tissue, or cellular sample from normal animals or the animal at an earlier time, wherein susceptibility to the disorder is based on the presence or amount of expression or activity of the SMC1 β polypeptide or the nucleic acid encoding the polypeptide of SMC1 β . In one embodiment, the disorder is selected from the group consisting of infertility, a pathological condition, and a nondisjunction syndrome.

The present invention also contemplates compositions comprising exogenous SMC1 β or agents that induce SMC1 β expression or activity and a pharmaceutically acceptable carrier. In one embodiment, the agent is selected from the group consisting of: a nucleic acid construct that encodes SMC1 β polypeptide, SMC1 β polypeptide, a small molecule agonist of SMC1 β and a SMC1 β peptidomimetic agonist. In another embodiment, the pharmaceutically acceptable carrier is an adjuvant, solubilizer, stabilizer, diluent, anti-oxidant, liposome, micelle, or patch.

The present invention also contemplates compositions comprising agents that reduce SMC1 β expression or activity and a pharmaceutically acceptable carrier. In one embodiment, the agent is selected from the group consisting of: a nucleic acid construct that encodes SMC1 β in an antisense orientation, a selective binding agent of SMC1 β polypeptide, a small molecule antagonist of SMC1 β , and a SMC1 β peptidomimetic antagonist. In another embodiment, the pharmaceutically acceptable carrier is an adjuvant, solubilizer, stabilizer, diluent, anti-oxidant, liposome, micelle, or patch. In a further embodiment, the polynucleotide is contained with a vector.

In another aspect, the invention contemplates diagnostic reagents. Such diagnostic reagents generally comprise a detectably labeled polynucleotide encoding the SMC1 β polypeptide, or a fragment, variant or homolog thereof. In one embodiment, the labeled polynucleotide is a first-strand cDNA.

A further aspect of the invention provides for methods for detecting the presence of SMC1 β nucleic acids in a biological sample. Such a method comprises the steps of: a) providing a biological sample suspected of containing SMC1 β nucleic acids; b) contacting the biological sample with a diagnostic reagent comprising a detectably labeled polynucleotide encoding the SMC1 β polypeptide, or a fragment, variant or homolog thereof

under conditions, wherein the diagnostic reagent will hybridize with SMC1 β nucleic acids contained in the biological sample; c) detecting hybridization between SMC1 β nucleic acid in the biological sample and the diagnostic reagent; and d) comparing the level of hybridization between the biological sample and diagnostic reagent with the level of hybridization between
5 a known concentration of SMC1 β nucleic acid and the diagnostic reagent. In one embodiment, the polynucleotide molecule is DNA. In another embodiment, the polynucleotide molecule is RNA.

The present invention also provides methods for detecting the presence of SMC1 β nucleic acids in a tissue or cellular sample. Such methods generally comprise the
10 steps of: a) providing a tissue or cellular sample suspected of containing SMC1 β nucleic acids; b) contacting the tissue or cellular sample with a diagnostic reagent comprising a detectably labeled polynucleotide encoding the SMC1 β polypeptide, or a fragment, variant or homolog thereof under conditions, wherein the diagnostic reagent will hybridize with SMC1 β nucleic acids; c) detecting hybridization between SMC1 β nucleic acid in the tissue or cellular
15 sample and the diagnostic reagent; and d) comparing the level of hybridization between the tissue or cellular sample and diagnostic reagent with the level of hybridization between a known concentration of SMC1 β nucleic acid and the diagnostic reagent. In one embodiment, the polynucleotide molecule is DNA. In another embodiment, the polynucleotide molecule is RNA.

20 In another aspect, the invention provides methods for screening agents that modulate meiosis in germ cells. Such methods generally comprise: a) providing a cell expressing SMC1 β ; b) contacting the cell with a candidate modulating agent; and c) monitoring the cell for a change in meiotic activity in the presence and absence of modulating agent; and wherein an alteration in meiosis indicates that the agent is a meiosis modulating
25 agent. In one embodiment, the modulating agent increases meiosis. In another embodiment, the modulating agent decreases meiosis. In other embodiments, the cell may be a spermatocyte or an oocyte. In a further embodiment, the cell is from a transgenic, non-human animal. In certain embodiments, the contacting of the cells with modulating agents may be carried out either in vitro or in vivo. In other embodiments, the candidate modulating agent
30 may be selected from the group consisting of: a nucleic acid construct that reduces the expression or activity of SMC1 β , a nucleic acid construct that increases the expression or

activity of SMC1 β , an antibody of SMC1 β , a small molecule antagonist of SMC1 β , and a peptidomimetic antagonist of SMC1 β .

In yet another aspect, the invention provides for compositions comprising candidate modulating agent of meiosis identified by the methods described herein and a pharmaceutically acceptable carrier. In one embodiment, the pharmaceutically acceptable carrier is an adjuvant, solubilizer, stabilizer, diluent, anti-oxidant, liposome, micelle, or patch.

A further aspect of the invention provides a method of modulating levels of SMC1 β in an animal. Such a method generally comprises administering to the animal the composition comprising a candidate modulating agent of meiosis identified by the methods described herein and a pharmaceutically acceptable carrier.

Another aspect provides a method of modulating meiosis in an animal. Such a method generally comprises administering to the animal the composition comprising a candidate modulating agent of meiosis identified by the methods described herein and a pharmaceutically acceptable carrier.

The invention also contemplates methods for screening agents that modulate SMC1 β expression or activity in germ cells. Such methods generally comprise the following steps: a) providing a cell expressing SMC1 β ; b) contacting the cell with a candidate modulating agent; and c) monitoring the cell for a change in SMC1 β expression or activity in the presence and absence of modulating agent; and wherein an alteration in SMC1 β expression or activity indicates that the agent is a SMC1 β modulating agent.

The invention further contemplates methods for screening agents that modulate SMC1 β expression or activity in germ cells. Such methods generally comprise the following steps: a) providing somatic cells with an inducible expression construct of SMC1 β ; b) contacting the cells with a candidate inhibitor of SMC1 β ; and c) monitoring the cells for an increase in proliferation; wherein an increase in cell proliferation indicates that the agent is a SMC1 β inhibiting agent.

In another aspect, the invention contemplates a composition comprising a candidate modulating agent of meiosis or SMC1 β expression or activity identified according to the method for screening agents described herein and a pharmaceutically acceptable carrier.

In one embodiment, the pharmaceutically acceptable carrier is an adjuvant, solubilizer, stabilizer, diluent, anti-oxidant, liposome, micelle, or patch. Another embodiment of the

invention provides methods of modulating levels of SMC1 β in an animal comprising administering to the animal the composition comprising the modulating agent(s). In a further embodiment, the invention provides methods of modulating meiosis in an animal comprising administering to the animal the composition comprising the modulating agent(s).

5 The present invention also provides transgenic non-human animals whose genomes comprise a homozygous null mutation in the endogenous SMC1 β gene, wherein the non-human animal exhibits abnormal development of the germ cells. In one embodiment, the transgenic non-human animal is a mouse.

10 The invention further provides isolated cells, or a purified preparation of cells, from a transgenic non-human animal whose genome comprises a homozygous null mutation in the endogenous SMC1 β gene, wherein production of functional SMC1 β is inhibited.

15 In a different aspect, the invention provides methods of evaluating a fertility treatment. Such methods generally comprise: a) administering the treatment to a transgenic mouse whose genome comprises a homozygous null mutation in the endogenous SMC1 β gene, wherein the mouse exhibits abnormal development of the germ cells and is infertile; and b) determining the effect of the treatment on fertility of the mouse, thereby evaluating the fertility treatment. In one embodiment, the treatment is evaluated in vivo, while in a different embodiment the treatment is evaluated in vitro. Furthermore, in other embodiments, the treatment may be determined by sperm count, testicular size, oocyte morphology, sperm
20 morphology, gamete morphology, chromosome morphology, the ability of chromosomes to pair, the ability of the mice to mate and produce offspring, the ability of the mice to have normal estrous cycles, and ovarian morphology.

25 The invention also contemplates an expression construct comprising a nucleic acid encoding a SMC1 β polypeptide, fragment, or variant thereof and a heterologous germ cell specific promoter operably linked to the construct. In a certain embodiment, the nucleic acid is in a sense orientation with respect to the promoter. In a different embodiment, the nucleic acid is in an antisense orientation with respect to the promoter. In one embodiment, the construct is contained within a viral vector. In a further embodiment, the promoter is a testis specific promoter. Still further, the promoter is phosphoglycerate kinase 2. In a
30 different embodiment, the promoter is an oocyte specific promoter.

 The invention also contemplates recombinant host cells, wherein the cells are transformed with the any of the constructs described herein. Still further, the invention

contemplates compositions comprising any of the constructs of described herein and a pharmaceutically acceptable carrier. In one embodiment, the pharmaceutically acceptable carrier is an adjuvant, solubilizer, stabilizer, diluent, anti-oxidant, liposome, micelle, or patch.

5 In another aspect, the invention contemplates a device, comprising: a) a membrane suitable for implantation; and b) the composition comprising any of the constructs described herein encapsulated within the membrane, wherein the membrane is permeable to the composition.

10 In yet another aspect, the invention provides a device, comprising: a) a membrane suitable for implantation; and b) the recombinant host cells transformed with any of the constructs described herein encapsulated within the membrane, wherein the cells secrete polypeptide, and wherein the membrane is impermeable to materials detrimental to the cells.

15 In another aspect, the invention provides a selective binding agent that is an antibody or a fragment thereof of SMC1 β polypeptide. In one embodiment, the antibody or fragment thereof specifically binds SMC1 β polypeptide. In a still further embodiment, the antibody is a monoclonal antibody.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

20 Germ-cell specific proteins are target candidates in the regulation and/or manipulation of fertility and infertility. SMC1 β , a germ cell-specific protein, was isolated from mammalian testis nuclear extracts and identified to be a mammalian meiosis-specific SMC protein (Revenkova *et al.*, *supra*, 2001). SMC1 β was found to be exclusively expressed in meiotic cells, starting with the leptotene phase of meiosis I, and continues to be expressed until metaphase of meiosis II. In meiotic cells, SMC1 β localizes to the core of
25 meiotic chromosomes.

A role for SMC1 β in sister chromatid cohesion of meiotic chromosomes throughout meiosis I and meiosis II has also been revealed. Evidence indicates that SMC1 β , within a multiprotein complex, is acting as the "clamp" that holds sister chromatids together during meiosis (Revenkova *et al.*, *supra*, 2001). This phenomenon is absolutely required for
30 meiotic progression and thus for spermatogenesis and oogenesis. Consequently, the absence

of SMC1 β has been shown to have a deleterious effect on spermatogenesis and is thought to have a deleterious effect on oogenesis.

The present invention addresses a role for SMC1 β in the regulation of fertility and infertility. More specifically, the present invention contemplates methods for inducing
5 fertility (or effecting contraception) and treating infertility. The inventors of the present application have shown that mutations in SMC1 β resulted in infertility. More specifically, the inventors discovered that mutations in SMC1 β inhibited meiosis in germ cells, especially at prophase I or later. In addition, it was determined that both female and male mice were infertile as a result of this mutation. These observations showed that normal
10 SMC1 β expression or activity is an essential step in the process of gametogenesis. Thus, these findings provide the first evidence of a role for SMC1 β in the regulation of gametogenesis and fertility.

Discussed in further detail herein below are the mechanisms by which mutations in SMC1 β lead to the inhibition of meiosis and infertility. Furthermore, the
15 present findings provide insights into the role of SMC1 β in normal fertility. Also described are methods and compositions for making and using various animal models of SMC1 β . The transgenic mouse knockout and knockin models will likely serve as useful models for the exploration of potential mechanisms of SMC1 β 's role in gametogenesis. Such models may also be used in assays to identify factors that cooperate with loss of wild-type SMC1 β in the
20 regulation of meiosis and gametogenesis and to develop agents for the therapeutic intervention of fertility and infertility.

Definitions

25 The term "infertility" refers to the state of not being fertile or not being able to conceive offspring. It may be a temporary state, such as that which is induced by a method of contraception or it may be a permanent state, which may be of known or unknown etiology. Infertility may occur in either the male or the female or both.

The term "agent that inhibits SMC1 β expression or activity" refers to any
30 molecule or molecules (e.g., nucleic acid, binding agent, antibody, peptibody, etc.) which can act directly or indirectly to downregulate expression or activity of the SMC1 β polynucleotide or polypeptide and block the subsequent expression or activity of SMC1 β .

The term "agent that induces SMC1 β expression or activity" refers to any molecule or molecules (*e.g.*, nucleic acid, polypeptide, etc.) which can act directly or indirectly to upregulate expression or activity of the SMC1 β polynucleotide or polypeptide and induce the subsequent expression or activity of SMC1 β .

5 The term "nucleic acid construct" refers to any nucleic acid molecule or molecules (*e.g.* either alone or in conjunction with a vector, promoter, enhancer, terminator, etc.). This term includes, but is not limited to, DNA, RNA, oligonucleotides, including upstream and downstream regulators of nucleic acid expression.

10 The terms "effective amount" and "therapeutically effective amount" each refer to the amount of an SMC1 β polypeptide, an SMC1 β nucleic acid molecule, or an agent that induces SMC1 β expression or SMC1 β activity used to support an observable level of one or more biological activities of the SMC1 β polypeptide set forth herein.

15 The term "expression vector" refers to a vector which is suitable for use in a host cell and contains nucleic acid sequences which direct and/or control the expression of heterologous nucleic acid sequences. Expression includes, but is not limited to, processes such as transcription, translation, and RNA splicing, if introns are present.

20 The term "host cell" is used to refer to a cell which has been transformed, or is capable of being transformed with a nucleic acid sequence and then of expressing a selected gene of interest. The term includes the progeny of the parent cell, whether or not the progeny is identical in morphology or in genetic make-up to the original parent, so long as the selected gene is present.

25 The terms "pharmaceutically acceptable carrier" or "physiologically acceptable carrier" as used herein refer to one or more formulation materials suitable for accomplishing or enhancing the delivery of the SMC1 β polypeptide, SMC1 β nucleic acids molecule, or SMC1 β selective binding agent as a pharmaceutical composition.

30 The term "selective binding agent" refers to a molecule or molecules having specificity for a SMC1 β polypeptide. As used herein the terms "specific" and "specifically" refer to the ability of the selective binding agents to bind to SMC1 β polypeptides and not to bind to non- SMC1 β polypeptides. It will be appreciated, however, that the selective binding agents may also bind orthologs of the SMC1 β polypeptide.

The term “transduction” is used to refer to the transfer of genes from one bacterium to another, usually by a phage. “Transduction” also refers to the acquisition and transfer of eukaryotic cellular sequences by retroviruses.

5 The term “transfection” is used to refer to the uptake of foreign or exogenous DNA by a cell, and a cell has been “transfected” when the exogenous DNA has been introduced inside the cell membrane. A number of transfection techniques are well known in the art and are disclosed herein. See, for example, Graham *et al.*, *Virology*, 52: 456, 1973; Sambrook *et al.*, *Molecular Cloning, A Laboratory Manual*, Cold Spring Harbor Laboratories (New York, 1989); Davis *et al.*, *Basic Methods in Molecular Biology*, Elsevier, 1986; and
10 Chu *et al.*, *Gene*, 13: 197, 1981. Such techniques can be used to introduce one or more exogenous DNA moieties into suitable host cells.

The term “transformation” as used herein refers to a change in a cell’s genetic characteristics, and a cell has been transformed when it has been modified to contain new DNA. For example, a cell is transformed where it is genetically modified from its native
15 state. Following transfection or transduction, the transforming DNA may recombine with that of the cell by physically integrating into a chromosome of the cell, it may be maintained transiently as an episomal element without being replicated, or it may replicate independently as a plasmid. A cell is considered to have been stably transformed when the DNA is replicated with the division of the cell.

20 The term “vector” is used to refer to any molecule (*e.g.*, nucleic acid, plasmid, or virus) used to transfer coding information to a host cell.

The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described therein. All references cited in this application are expressly incorporated by reference herein.

25

A. Involvement of SMC in Chromosome Dynamics

The present section provides a description of the involvement of structural maintenance of chromosome (SMC) proteins in DNA and chromatin dynamics to the extent that such a description will facilitate a better understanding of the methods and compositions
30 of the present invention.

SMC1 β belongs to the family of SMC proteins, whose members act in DNA and chromatin dynamics. In particular, they are essential for chromosome condensation and

sister chromatid cohesion, and involved in DNA repair and recombination. All these processes are at the heart of meiosis, but have been specifically modified to serve the purpose of generating germ cells. Strong evidence suggests that SMC1 β , which exists only in higher eukaryotes, is central to meiotic sister chromatid cohesion and DNA recombination. Its function is highly likely to be strictly controlled in a meiosis stage-specific and chromosomal location-specific manner. The expression of SMC1 β may be regulated by specific transcription factors and proteolysis/phosphorylation events. Thus, SMC1 β is a potential target for interfering with male meiosis.

Meiosis features unique and essential chromosome processes. These include the formation of meiosis-specific protein-DNA structures like the synaptonemal complex (SC), DNA recombination, and reductional segregation of chromosomes. There is accumulating evidence for a requirement for SMC proteins in these processes.

The evolutionary highly conserved eukaryotic SMC protein family includes six members named SMC1 to SMC6 and is involved in several key dynamic DNA and chromatin processes (reviews: Jessberger *et al.*, *Curr. Opin. Genet. Dev.* 8:254-259, 1998; Strunnikov, *Trends Cell Biol.* 8:454-459, 1998; Hirano, *Curr. Opin. Cell Biol.* 10:317-322, 1998; Hirano, *Genes Dev.* 13:11-19, 1999; Hirano, *Genes Dev.* 16:399-414, 2002; Strunnikov and Jessberger, *Europ. J. Biochem.* 263:6-13, 1999; Cobbe and Heck, *J. Struct. Biol.* 129:123-143, 2000; and Jessberger, *Nat. Rev. Mol. Cell Biol.* 3:767-778, 2002). The SMC family was first defined as such in 1994 and has since then attracted increasing attention. The first publication on mammalian SMC proteins was by Jessberger *et al.* (1996a). To date, the best documented processes in which SMC proteins are involved are chromosome condensation and sister chromatid cohesion. A role in DNA recombination and the response to DNA damage has also been demonstrated. A fourth role of SMC proteins (SMC2, SMC4) is in gene dosage compensation in nematodes (Chuang *et al.*, *Science* 274:1736-1738, 1996; Lieb *et al.*, *Cell* 92:1-20, 1998). The six subfamilies of SMC proteins can be grouped according to the three types of heterodimers that they form: SMC1/SMC3, SMC2/SMC4, and SMC5/SMC6. The SMC5 and SMC6 proteins (Spr18 and Rad18 proteins in *S. pombe*) belong to a more ancestral family and act in DNA repair (Lehmann *et al.*, *Mol. Cell Biol.* 15:7067-7080, 1995; Jones and Sgouros, *Genome Biol.* 2:RESEARCH0009, 2001). All the heterodimers constitute core components of larger multiprotein complexes that carry out specific functions. One of the major SMC complexes is condensin, which contains the SMC2/4 heterodimer and several non-SMC subunits, and is necessary for mitotic

chromosome condensation (Strunnikov *et al.*, *Genes and Dev.* 9:587-599, 1995; Sutani and Yanagida, *Nature*, 388:798-801, 1997; Hirano *et al.*, *Cell* 89:511-521, 1997).

The other heterodimer, SMC1/3 is a component of at least three protein complexes. Genetic studies in *S. cerevisiae* and biochemical analysis in *X. laevis* egg extracts
5 revealed a requirement for the SMC1/3 proteins in mitotic sister chromatid cohesion (Guacci *et al.*, *Cell* 91:47-58, 1997; Michaelis *et al.*, *Cell* 91:35-46, 1997; Losada *et al.*, *Genes Devel.* 12:1986-1997, 1998). The mitotic cohesin complex contains, besides SMC1/3, at least two other polypeptides, the Rad21 (Scc1p/Mcd1p), and the Scc3 proteins. The SMC1/3 heterodimer has also been identified as constituent of the recombination complex, RC-1,
10 which was isolated from bovine thymus and is present in a variety of somatic cells (Jessberger *et al.*, *Journ. Biol. Chem.* 268:15070-15079, 1993; Jessberger *et al.*, *EMBO-J.* 15:4061-4068, 1996; Stursberg *et al.*, *Gene* 228:1-12, 1999). RC-1 catalyzes SMC protein-dependent cell-free recombinational repair of gaps and deletions. The presence of the SMC1/3 heterodimer in these multiprotein complexes furthered speculations about an SMC-mediated functional link of sister chromatid cohesion and recombinational repair (Jessberger
15 *et al.*, *Curr. Opin. Genet. Dev.* 8:254-259, 1998; Hirano, *Curr. Opin. Cell. Biol.* 10:317-322, 1998; Strunnikov and Jessberger, *Europ. J. Biochem.* 263:6-13, 1999). This idea was supported by the recent report on DNA damage-dependent phosphorylation of SMC1 by ATM kinase (Kim *et al.*, *Genes & Dev.* 16:560-570, 2002; Yazdi *et al.*, *Genes Dev.* 16:571-
20 582, 2002).

Features of SMC proteins are determined by specific properties of their five domains. The N-terminal domains invariably contain an NTP binding motif, the Walker A box. The C-termini bear a DA box with a Walker B-like sequence and the LSGG signature motif, typical for the ABC ATPase family of proteins. The hinge domain is characterized by
25 a set of four highly conserved glycine residues often found in flexible regions in a protein, with the consensus sequence G(X)₆G(X)₃GG. While the N-terminal domain does not bind DNA, the C-terminal domain, hinge domain, and a coiled-coil domain do (Akhmedov *et al.*, *J. Biol. Chem.* 273:24088-24094, 1998; Akhmedov *et al.*, *J. Biol. Chem.* 274:38216-38224, 1999; Hirano *et al.*, *EMBO J.* 21:5733-5744, 2002). Most domains show a strong preference
30 for double-stranded (ds) DNA substrates, and a high specificity for dsDNA molecules, which are able to adopt secondary structures. Good binding substrates were also palindromic and/or A/T-rich sequences such as scaffold associated regions and centromer DNA-derived fragments (Akhmedov *et al.*, *J. Biol. Chem.* 273:24088-24094, 1998; Akhmedov *et al.*, *J.*

Biol. Chem. 274:38216-38224, 1999). Chromatin immunoprecipitation experiments confirmed the preferential localization of Smc3p or other cohesin components to A/T-rich and centromeric regions in yeast (Blat and Kleckner, *Cell* 98:249-259, 1999; Megee *et al.*, *Mol. Cell* 1999; Tanaka *et al.*, *Cell*, 98:847-858, 1999; and Laloraya *et al.*, *Cell Biol.* 151:1047-1056, 2000).

The hinge domain is thought to provide flexibility to the SMC molecules by allowing opening or closing of the two-armed structure. By electron microscopy, Melby *et al.* *J. Cell. Biol.* 142:1595-1604, (1998) demonstrated, for prokaryotic homodimeric SMC proteins, that the two arms of SMC molecules could move around the central hinge. These dimers are antiparallel, bearing an N- and C-terminus at each end. A series of pull-down assays using combinations of wildtype or mutant yeast SMC1 and SMC3 proteins expressed in insect cells, and crystal data from a bacterial homodimer, yielded data that support a model calling for a heterodimer made of SMC proteins folded back onto themselves, linked at their hinge domains, and potentially embracing DNA between its two arms.

In meiotic cells, meiosis-specific SMC complexes have evolved. Two of the non-SMC subunits of cohesin are replaced by meiosis-specific proteins: Rad21 is replaced by Rec8, and Scc3 by STAG3 (reviewed by Petronczki *et al.*, *Cell* 112:423-440, 2003). In 2001, the identification of a novel, meiosis-specific SMC protein was reported (Revenkova *et al.*, *Mol. Cell. Biol.* 21:6984-6998, 2001).

B. The Discovery of SMC1 β

The present section provides an overview of the discovery of SMC1 β to the extent that such an overview will facilitate a better understanding of the methods and compositions of the present invention.

Immunoprecipitation using anti SMC3 antibodies and testis nuclear extracts revealed an additional SMC protein, SMC1 β , identified as a meiosis-specific isoform of SMC1, hence renamed SMC1 α . SMC1 β displayed a chromosomal localization pattern much like SMC3, i.e. in spermatocytes it was found to be associated with the entire chromosome from prophase I until metaphase I. At that stage, it disappears from the chromosome arms, but it is retained at the centromeres, which are the sites of continued sister chromatid cohesion until metaphase/anaphase of meiosis II. At anaphase II, SMC3 and SMC1 β , along with Rec8, which behaves similar but not identically, dissociate also from the centromeres

allowing the sister chromatids to be separated. SMC1 α , however, is more loosely associated with the chromosomes, and disappears entirely during meiosis I (Eijpe *et al.*, *J. Cell Sci.* 113:673-682, 2000; Revenkova *et al.*, *Mol. Cell. Biol.* 21:6984-6998, 2001). Therefore, SMC1 β , but not SMC1 α , is now thought to be responsible for centromeric sister chromatid cohesion in meiosis. SMC1 β was also found at chiasmata and on bridges between homologous chromosomes in meiosis I and may thus be involved in meiotic recombination as well. Smc3p in *S. cerevisiae* has indeed been shown to be required for meiotic recombination and meiotic sister chromatid cohesion (Klein *et al.*, *Cell* 98: 91-103, 1999). However, there is no protein orthologue to SMC1 β in lower eukaryotes like yeast or even *C. elegans*. SMC1 β is highly conserved between mouse and man (82 % amino acid identity). These findings suggest that there are several different SMC-containing cohesin-like complexes with specialized functions in meiotic cells.

The compositions of the SMC1 β -based complex are not yet precisely known. There may be two SMC1 β complexes, one specific for the centromere, the other for the chromosome arms. It is also unknown how association and dissociation of SMC1 β from either the chromosome arms in meiosis I or the centromeres in meiosis II is regulated. Furthermore, it remains to be elucidated, how meiosis-specific expression of SMC1 β is achieved and timed.

The unexpected finding of a meiosis-specific SMC protein, and the initial characterization of SMC1 β was described in Revenkova *et al.*, *Mol. Cell. Biol.* 21:6984-6998, 2001. In that study it was determined that SMC1 β is an isoform of SMC1 α with amino acid identity in conserved domains of 45-79%; SMC1 β contains an unusual, highly basic 28 amino acid peptide at its C-terminus; SMC1 β forms a dimer with SMC3; SMC1 β protein is exclusively found in meiotic cells; SMC1 β , together with SMC3, localizes along the axial elements of the synaptonemal complex; and SMC1 β dissociates from meiotic chromosomes in two steps: from their arms at metaphase I, from their centromeres at metaphase II. It is highly likely that SMC1 β (and not SMC1 α) is very likely responsible for sister chromatid cohesion up to anaphase II. The expression of SMC1 β must be a strictly regulated process, and its function in association with meiotic chromosomes needs to be tightly controlled.

C. The SMC1 β Promoter

The present section provides a characterization of the SMC1 β promoter, which provides some insight into the regulation of the SMC1 β gene. The characterization of the SMC1 β promoter allows for better understanding and further development of the methods and compositions of the present invention. Such a promoter sequence may be used to drive the expression of SMC1 β -derived nucleic acid sequences in a variety of recombinant techniques described herein, or alternately may be used to effect germ cell-specific expression of non-SMC1 β nucleic acid sequences.

Northern blotting of RNA from a variety of mouse tissues was performed using a 616-bp 5' fragment of SMC1 β cDNA as a probe. This experiment confirmed testis-specific expression of the gene. The specific signal of about 4.5 kb was not seen in RNA from any other tissue. The same probe was also used to analyze RNA prepared from purified spermatocytes, and the same 4.5-kb mRNA was detected.

The mouse gene for SMC1 β is located on chromosome 15 (Ensemble gene ID ENSMUSG00000022432). The human homolog was found in a syntenic region on human chromosome 22 (human SMC1 β ; accession number NT_011522). In both genomes, the locus contains another gene (accession numbers AK016311 and AAH09904 are for mouse and human, respectively) located in close proximity to the SMC1 β gene. The two genes are arranged in a head-to-head configuration. In the mouse genome, the distance between the 5' end of the SMC1 β cDNA and the 5' end of the AK016311 cDNA is only 142 bp. In the human genome, the start of a cDNA clone and SMC1 β start codon are 162 bp apart. Therefore, it is very likely that the 5' region of the SMC1 β gene contains a bidirectional promoter, or two overlapping promoters.

The analysis of the human genome (Adachi and Lieber, *Cell* 109:807-809, 2002) revealed that a significant fraction of genes is organized in a divergent fashion with transcription start sites less than 1 Kb apart. For example, 319 genes located on chromosome 22 were analyzed, and 56 (18%) fell into this category. The fraction was even higher among the genes implicated in DNA repair (42 % among 120 genes analyzed). The physiologic role of such organization for most of the cases still has to be elucidated. At the SMC1 β locus the second gene encodes a 37-kDa protein product with unknown function. In human, transcripts of this gene were found in tumors, including germ cell tumors.

A striking characteristic feature of human bidirectional promoter regions is the presence of a CpG island between the genes (Adachi and Lieber, *Cell* 109:807-809, 2002). In the SMC1 β locus the CpG island occupies the region from position 330 bp upstream to 140 bp downstream of the SMC1 β start codon.

5 For analysis of the putative regulatory region upstream of the SMC1 β gene, and in order to attempt to create a SMC1 β deficient mouse, a BAC clone was isolated from a mouse genomic library. This BAC clone contains at least 6 kbp of sequence upstream of the SMC1 β start site. A 437 bp fragment derived from this BAC clone, which terminates 70 bp upstream of the SMC1 β start codon, was used as a probe for a Northern blot of total RNA
10 from adult mouse tissues to analyze transcription of the AK016311 gene. A transcript of approximately 1.6 kbp was detected in RNA from the testis and purified spermatocytes, but not from kidney.

The sequence from position 2100 upstream to position 200 downstream of the SMC1 β start codon was then analyzed by the PromoterInspector program, which predicts
15 RNA polymerase II promoter regions in mammalian genomic sequences (Scherf *et al*, *J. Mol. Biol.* 297:599-606, 2000, Genomatix, Munich, GERMANY). The program identified a 220 bp fragment containing the SMC1 β start codon as a promoter region. The program MatInspector (Genomatix, Munchen, GERMANY) was then used to identify potential transcription factor binding sites within this region. The same analysis was performed for the
20 corresponding human sequence. The sites conserved between the mouse and the human regions include potential binding sites for members of the transcription factor families RFX, E2F, and the retinoic acid receptor (RAR) family.

By the alignment of 5' regions of mouse and human SMC1 β genes, the human SMC1 β promoter region was identified as a potential promoter by the program
25 PromoterInspector. Putative binding sites for 3 families of transcription factors were identified: RFX- Regulatory factor X family, E2F- E2F family, and RAR – retinoic acid receptor family. The starting positions of SMC1 β cDNA and AK01631 cDNA were determined.

The RFX family of transcription factors contains 5 members in both the
30 human and the mouse. RFX1 is expressed ubiquitously and forms homodimers and heterodimers with RFX2 and RFX3. Highest expression level of these proteins was found in testes (Reith *et al*, *Mol Cell Biol* 14:1230-1244, 1994) but so far no testis-specific target

genes have been identified. RFX4 is closely related to RFX1-3 and detected only in testes (Morotomi-Yano *et al*, *J Biol Chem* 277:836-842, 2002). RFX4, transiently expressed in COS7 cells, interacts with RFX2 and RFX 3. Target genes controlled by RFX4 are unknown. In *S. pombe*, the RFX homolog, sak1, regulates exit from the mitotic cycle (Wu and McLeod, *Moll Cell Biol* 15:1479-1488, 1995).

The E2F family of transcription factors includes at least six members, which control genes involved in DNA replication and repair, cell proliferation, differentiation and apoptosis (reviewed in Stevaux and Dyson, *Curr. Opin. Cell Biol.* 14:684-691, 2002). Knockout mice lacking E2F1 displayed testicular atrophy and developed a variety of tumors, predominantly reproductive tract sarcomas (Yamasaki *et al.*, *Cell* 85:537-548, 1996). The overexpression of E2F1 in transgenic mice also caused testicular atrophy and sterility as a result of increased apoptosis in the germinal epithelium (Holmberg *et al.*, *Oncogene* 17:143-155, 1998).

Retinoic acid receptors control numerous genes involved in cell proliferation and differentiation (reviewed in Wei, *Annu. Rev. Pharmacol. Toxicol* 43:47-72, 2003). There are two classes of nuclear receptors binding retinoids, RAR and RXR. RAR α plays a critical role in spermatogenesis as demonstrated by mouse knockout studies. Disruption of the RAR α gene causes degeneration of meiotic and post-meiotic testicular cells, similar to that observed in vitamin A-deficient animals (Lufkin *et al.*, *Proc Natl Acad Sci USA* 90:7225-7229, 1993).

D. Making and Using Transgenic Animals of the Invention

Particular aspects of the present invention involve the production of transgenic animals. In particular, the first set of transgenic mice contemplated by the present invention are those which have a loss of the SMC1 β phenotype. The second set of transgenic mice are those that conditionally express SMC1 β . The rationale and methods and compositions for the production of these transgenic animals are provided in further detail herein below.

Those of skill in the art are aware of general techniques for making transgenic animals. Such techniques involve the integration of a given nucleic acid construct into the genome in a manner that permits the expression of a transgene or the knockout of an existing gene. Methods for producing transgenic animals are generally described by Wagner and Hoppe (U.S. Patent No. 4,873,191, which is incorporated herein by reference), Palmiter and

Brinster (*Cell* 41:343-345, 1985, which is incorporated herein by reference in its entirety), and in "Manipulating the Mouse Embryo; A Laboratory Manual" 2nd edition (eds. Hogan, Beddington, Costantini and Long, Cold Spring Harbor Laboratory Press, 1994, which is incorporated herein by reference in its entirety). In the present application, the genes of
5 interest are SMC1 β and SMC1 β -related genes. The wild-type SMC1 β sequence is known to those of skill in the art (see *e.g.*, Accession No. AF303827), as may be used as the underlying sequence for the production of the transgenic mice.

Typical techniques for producing transgenic animals involve the transfer of genomic sequences by microinjection into a fertilized egg. The microinjected eggs are
10 implanted into a host female, and the progeny are screened for the expression of the transgene. Transgenic animals may be produced from the fertilized eggs from a number of animals including, but not limited to, reptiles, amphibians, birds, mammals, and fish. Methods for the production and purification of DNA for microinjection are described in Hogan *et al.*, *Manipulating the Mouse Embryo* (Cold Spring Harbor Laboratory, Cold Spring
15 Harbor, NY, 1986), in Palmiter *et al.* *Nature* 300:611 (1982); *the Qiagenologist, Application Protocols*, 3rd edition, published by Qiagen, Inc., Chatsworth, CA.; and in Sambrook *et al.* *Molecular Cloning: A Laboratory Manual* (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1989).

The first set of transgenic animals of the present invention provide a model for
20 determining whether the loss of SMC1 β is sufficient for inducing infertility. Because the SMC1 β and AK016311 genes are located very close to each other in a divergent orientation, it was assumed that it would be hardly possible to delete the first exon of SMC1 β without affecting the expression of the AK016311 gene. The phenotype of the resulting mice would be very difficult to interpret. Therefore, the best approach was determined to be the deleting
25 one of the central exons of SMC1 β , which is located far downstream from the AK016311 gene. The amino acid sequence encoded by exon 10 of SMC1 β comprises a large part (40%) of its hinge domain. The hinge domain has been shown to be essential for the formation of the SMC heterodimers, and there is direct evidence for dimer formation by the SMC1 β and SMC3 hinge domains. The SMC1 β -SMC3 hinge domain, like other hinge domain dimers, is
30 also required for DNA binding *in vitro* (Hirano and Hirano, *EMBO J.* 21:5733-5744, 2002; and Revenkova *et al.*, *Mol. Cell. Biol.*, 2001, in preparation) and may play a role in SMC-DNA interactions. Therefore, it was assumed that removing a large part of the hinge region would result in a non-functional protein. In addition, stop codons are present in the selective

marker gene (neo) introduced in place of exon 10. Even in case the selective marker replacing exon 10 was transcriptionally skipped in the transgenic mouse, the resulting SMC1 β protein, with a deletion of most of the hinge region, would be nonfunctional.

To generate a knockout construct, a probe derived from SMC1 β cDNA was used to screen a mouse (strain 129SvJ) genomic library. The screen yielded one BAC clone that carried at least 21 kb of genomic DNA, which spanned about 6 kb of 5' upstream region and at least 11 exons of SMC1 β . The identity of the sequence was confirmed by partial sequencing and restriction endonuclease digestion. Several genomic DNA fragments were subcloned, and a 9.6 kb *Bam*HI fragment, which spanned exons 8 to 11, was used for the generation of the targeting construct. A 7.8 kb subfragment of genomic DNA was subcloned into pBluescriptSK 3' of a thymidine kinase gene, which served for selection against random integrants. In the plasmid, the neomycin resistance marker gene replaced a 1.2-kb fragment containing SMC1 β exon 10. The neomycin resistance gene was inserted in direct orientation in respect to SMC1 β to avoid the production of antisense transcripts.

The construct was electroporated into W4/129S6 embryonic stem (ES) cells (Taconic Inc.). Production and analysis of targeted ES clones was performed as described (Matisse *et al*, *Production of targeted embryonic stem cell clones*, In: Gene targeting: a practical approach, Chapter 3, Joyner A.L. (e.d.), Oxford University Press, New York, 2000). Four independent ES clones were isolated in which neomycin resistance marker replaced SMC1 β exon 10. The frequency of targeted transformants was 1% (4/395 screened) homologous recombinants per total transformants. The structure of the targeted locus was verified by Southern hybridization of ES genomic DNA digested with *Bam*HI with two external probes upstream and downstream of the targeted site. Blastocyst injection of the ES cells from four clones, followed by implantation into foster mothers, was performed by the Mount Sinai Mouse Genetics shared facility. All four ES clones gave rise to male chimeric mice (up to 90 % chimeric based on fur color; total number 16), which were mated with C57Bl/6 females to obtain heterozygous offspring. For all four lines, germline transmission based on fur color was observed in F1. Genomic DNA from F1 offspring was isolated, digested with *Bam*HI, and analyzed by Southern hybridization with probe L. Fourteen females and 14 males, heterozygous for the SMC1 β locus, were obtained. Heterozygous animals were mated to generate SMC1 β ^{-/-} progeny, or outcrossed with C57Bl/6 to transfer the mutation into an inbred strain genetic background. The *Bam*HI digested tail DNA of F2 progeny of heterozygous animals was analyzed by Southern hybridization with probe L.

Among the first 14 animals analyzed, two females and one male, homozygous for the disrupted SMC1 β locus, were found. The SMC1 β ^{-/-} mice appeared normal, suggesting that SMC1 β is dispensable for survival and growth up to at least six weeks of age. At four weeks of age, the homozygous male and its wildtype and heterozygous siblings were sacrificed and testes were analysed. Testes from the wildtype and heterozygous animals were of similar size and weight; however, the testes from the SMC1 β ^{-/-} animal were half the size and weight. Immunofluorescence staining of testes sections with SMC1 β monoclonal antibodies as described by Revenkova *et al. Mol. Cell. Biol.* 21:6984-6998, (2001) was carried out. As observed earlier in the wildtype mouse, antibodies stained compact chromosomal axes in prophase I nuclei. No staining specific for SMC1 β was detected in the testis of ^{-/-} animals. Staining of nuclei with propidium iodide revealed that while the wild-type seminiferous tubules contained multiple layers of cells, the seminiferous tubules of the SMC1 β -deficient animal had fewer cell layers and appeared comparatively empty. Homozygous SMC1 β ^{-/-} animals have appeared to be viable and have survived at least until four months of age now. The fertility of homozygotes is being evaluated; histological and cytological analysis of the reproductive organs is being carried out. Using these mice, it is possible to determine whether the knock-out of SMC1 β alone leads to the loss of fertility.

Mouse genomic DNA was probed using Southern blotting analysis for the SMC1 β gene. DNA from wildtype mice revealed a 9.6 kbp band representing the wildtype SMC1 β allele. DNA from knock-out mice revealed a 6.3 kbp band representing the knockout allele. DNA from heterozygous mice revealed both alleles.

Immunofluorescence staining with anti SMC1 β antibody (FITC-labeled; green) of wildtype or homozygous knockout mouse testes was carried out on testis sections from 4 week-old littermates. There was an absence of chromosomal staining in the seminiferous tubules of the knockout mouse.

Initial analysis of the testis and of spermatogenesis in the SMC1 β knock-out mouse strain was performed. The testis in the four-week old SMC1 β -deficient mouse is half the size and half the weight of a wildtype testis. With increasing age, this difference increased.

Testis morphology was examined by histological staining of testis tissue sections in four week-old littermates (wildtype, heterozygous, and knockout mice). The

seminiferous tubules in the knock-out mice did not contain any mature spermatozoa. Cross-sections of the seminiferous tubules revealed no late stage spermatids, and the tubules were of reduced size. Spermatogenesis was blocked at prophase of meiosis I. Most cells appeared to be arrested at the leptotene/zygotene stage, with only a few cells that progressed up to the pachytene stage. There were no cells that progressed further than prophase I. Premeiotic cells, such as spermatogonia were unaffected, consistent with the onset of SMC1 β expression in early meiosis (leptotene) in wildtype mice.

Periodic acid/Schiff staining of mouse testis sections from 11 week-old littermates at the same magnification showed seminiferous tubules of reduced size in knockout mice and the centers of the tubules of knockout mice were devoid of spermatids. The testis weights were 216 mg for heterozygotes, and 52 mg for knockout mice.

Testis sections from 11 week-old littermates were also assayed for apoptosis by the TUNEL assay, which visualizes broken DNA, a hallmark of apoptosis. In a normal, wildtype testis, one usually finds a small number of apoptotic cells, often premeiotic cells, occasionally meiotic cells. In the SMC1 β knockout testis, the total number of apoptotic cells was only mildly increased. Most of the apoptotic cells were of the early meiotic types (leptotene/zygotene). This indicated that there is no large accumulation of dying or dead cells in the seminiferous tubules of knockout mice. Otherwise, the SMC1 β -deficient testis may also be not as small as observed. Rather, arrested cells are removed from the system, probably through absorption by the somatic Sertoli cell layer. Sertoli cells are known to have some phagocytic function.

Studies of oogenesis in the SMC1 β -deficient females are being performed. Because most known mouse mutants that affect meiosis have quite different phenotypes in females compared to males (Hunt and Hassold, *Nature Rev. Genetics* 2: 280-291, 2002), it is being investigated as to how female meiosis (oogenesis) is blocked in comparison with that seen for spermatogenesis. Also, female meiosis, due to the very long dictyate arrest at the end of prophase I, has its specifics and is in some ways more complicated than male meiosis. Initial studies have indicated that SMC1 β -deficient females are sterile. To date, more studies have concentrated on spermatogenesis. However, SMC1 β is a potential target for the inhibition of oogenesis as well.

Fertility tests are currently underway. Breeding pairs have been set up with either a SMC1 β -deficient male mouse or a SMC1 β -deficient female mouse, together with the

respective wildtype partner. After many weeks of breeding, i.e. more than four reproductive cycles, no progeny have been obtained in any breeding with SMC1 β -deficient mice.

Naturally-occurring deficiencies in a key meiosis-specific protein like SMC1 β likely causes infertility. Infertility is a very common medical problem that affects about 10 % of couples and has a significant familial component, with autosomal-recessive inheritance accounting for half of the male cases. Meiotic arrest is the most common type of sperm maturation arrest in men with non-obstructive azoospermia.

Thus, artificially disabling SMC1 β may indeed turn into an advantage for regulating reproduction, i.e. for contraception. Conceptually it is very attractive to look for a target that is both highly important and highly specific for meiosis and SMC1 β fulfills both requirements.

The data presented herein support the use of SMC1 β as a target for a male contraceptive drug. Eliminating functional SMC1 β should block male meiosis in humans and thus render the individuals sterile. This protein is also an attractive target because of its potential for contraceptive reversibility. Stopping drug treatment, which inhibits the expression of SMC1 β , would allow for the quick reestablishment of fertility (one meiotic cycle at the most).

E. Regulation of SMC1 β by Proteolysis

The present section provides a summary of what is known about the role(s) that protein phosphorylation and/or protein degradation play in the proteolysis and regulation of SMC1 β . This summary may be helpful to the extent that it provides insight into the methods and compositions of the present invention.

In mitotic cells, the association of cohesin with the sister chromatids is terminated by targeted proteolysis of one subunit of cohesin, the Scc1/Rad21 protein (Uhlmann, *Curr. Opin. Cell Biol.* 13:754-761, 2001). In yeast, Scc1p is phosphorylated during metaphase of mitosis by the Polo-like kinase Cdc5, and then cleaved by an endopeptidase called separase (Uhlmann *et al.*, *Nature* 400:37-42, 1999; Uhlmann *et al.*, *Cell* 103:375-386, 2000). Separase itself gets activated by ubiquitin-dependent degradation of its inhibitor, securin. In higher eukaryotes, two distinct pathways are responsible for dissociation of cohesin from the chromosomes (Waizenegger *et al.*, *Cell* 103:399-410, 2000). Most of

cohesin, primarily at the chromosome arms, is removed by phosphorylation through a Polo-like kinase, early in mitosis, at the prophase/metaphase transition. The residual cohesin, however, which is mostly associated with the centromeric regions, is removed from the chromosomes by separase cleavage of Scc1, similar to the situation in yeast. Thus, in mitosis,
5 a combined action of phosphorylation and specific protein degradation is required to dissociate cohesin from the right region at the right time.

Little is known about the mechanism by which dissociation of meiotic cohesin is regulated and achieved in mammalian cells. The dissociation of the SMC1 β /SMC3 complex occurs in a two-step process: first, the complex is removed from the chromosome
10 arms during metaphase I, and homologs, each consisting of two sister chromatids linked at their centromeres only, are segregated (Revenkova *et al.*, *Mol. Cell. Biol.* 21: 6984-6998, 2001). In a second step, the remaining centromeric complex dissociates at the metaphase/anaphase II transition to allow segregation of the individual sister chromatids. Destruction of cohesion in the chromosome arms appears to be required for resolution of
15 meiotic crossovers.

It is very likely, that phosphorylation and/or protein degradation play an important role in regulating the removal of SMC1 β and its complex from meiotic chromosomes. Understanding this mechanism would fill a significant gap in our knowledge of the meiotic process and of regulation of SMC1 β function. It is unlikely that association
20 and dissociation of cohesins are regulated exclusively through Rec8, because Rec8 behaves differently from SMC1 β and SMC3 (Eijpe *et al.*, *J. Cell Biol.* 160:657-670, 2003; and see below). As a first approach to address this question, a series of proteolysis assays were undertaken. In these assays, nuclear extracts from mouse testis were incubated under various conditions and investigated the intactness of SMC1 β by immunoblotting .

25 The data indicated a progressive degradation of SMC1 β with a 120-kDa intermediate being generated, but then quickly degraded as well. Addition of ATP increased the efficiency of the reaction. Interestingly, while the other cohesin subunits Rec8 or STAG3 (which may associate also with the SMC1 α /SMC3 complex) were also degraded, their degradation was not enhanced by addition of ATP, but rather inhibited. This argues for an
30 activity that is specific or specifically regulated for SMC1 β . The ATP effect may indicate either an ATP-dependent activation of the protease (e.g. by phosphorylation or by an indirect mechanism such as ATP-dependent removal of an inhibitor), or an ATP-dependent targeting

of SMC1 β for degradation. For example, phosphorylation of SMC1 β may trigger its degradation.

To begin testing the effect of phosphorylation, nuclear extracts were prepared in the presence or absence of general phosphatase inhibitors (1 mM o-vanadate, 10 mM β -glycerophosphate). If a phosphorylated SMC1 β is more prone to degradation, inhibited dephosphorylation should stimulate degradation. The data showed that this is the case. The effect of phosphatase inhibition can either be direct – on SMC1 β phosphorylation – or indirect, i.e. on maintaining an activated state of the protease or of a regulator of the protease. The mechanism of phosphatase inhibition and the identification of enzymes that are involved are currently being examined.

Speculating that the 120-kDa product seen in degradation assays is a true intermediate of SMC1 β degradation, two fragments of SMC1 β that span either one of the two putative regions of cleavage, positioned at about 30 kDa distance from each of the termini, were subcloned and expressed in *E. coli*. Thus, an N-terminal or a C-terminal polypeptide of 33 or 35 kDa, respectively, was expressed and purified. While the N-terminal fragment was purified to near homogeneity (100 mM imidazole fraction), there were one major and a few minor contaminants in the C-terminal fragment preparation. The putative region of cleavage was identified at the center of these polypeptides (N-terminal fragment: amino acids 174 to 420; C-terminal fragment: amino acids 820 to 1073). These proteins were used in cleavage inhibition assays. The data indicated that increasing amounts of the N-terminal protein, but not of the C-terminal protein, inhibited the degradation of SMC1 β . Experiments are being repeated with more highly purified material, even though degradation was not affected by the C-terminal preparation. Thus, there is early evidence for a cleavage site within the N-terminal region between amino acids 174 and 420, and the precise cleavage site is being determined.

Analyzing the amino acid sequence within that N-terminal region for known protease cleavage sites (peptide cutter program; The ExPASy (Expert Protein Analysis System) proteomics server of the Swiss Institute of Bioinformatics, Geneva, SWITZERLAND) revealed a large number of sites for enzymes like trypsin, thermolysin, pepsin and that like, but only one site for the enzyme proline-endopeptidase (PEP). This site is at the center of the region. In addition, there are three cleavage sites for separase close together at the very C-terminal end of this region, making it perhaps somewhat less likely to

be cleaved by separase (because the resulting SMC1 β fragment would only be about 103 kDa, and would have to run abnormally high to appear as a 120-kDa band). The full-length SMC1 β sequence demonstrated several more sites for each of these two enzymes, including a separase site in the C-terminal region, which, however, does not act as an inhibitor.

5 Consensus sequences for both sites are not very restrictive (H/K/R-P-X [notP] for PEP, and S/D/E/I/G-X -E/D-X-X-R for separase). Based on these studies, it is very plausible that a cleavage signal like phosphorylation is specifying the actual clavage site. *In vitro*, most members of the PEP family, however, cleave only short oligopeptides, although the crystal structure may accomodate larger substrates (Polgar, *Cell. Mol. Life Sci.* 59:349-362, 2002).

10 *In vivo* substrates of PEP are largely unknown and likely relatively small peptides (e.g. peptide hormones), but a role for PEP in the meiosis and maturation of sperm was proposed based on its expression profile and results of inhibition experiments (Kimura *et al.*, 2002). Thus, a role for PEP in the cleavage of SMC1 β seems not very likely, but cannot be entirely ruled out. In light of its known function in regulating mitotic cohesin, a role for separase

15 appears more plausible.

F. Assaying for Other Modulators of SMC1 β Polypeptide Activity

Particular aspects of the present invention contemplate the modulation of SMC1 β polypeptide expression or activity. In particular, methods of identifying modulators

20 of SMC1 β polypeptide expression or activity are provided in further detail herein below.

In some situations, it may be desirable to identify molecules that are modulators, *i.e.*, agonists or antagonists, of the expression or activity of SMC1 β polypeptide. Natural or synthetic molecules that modulate SMC1 β polypeptide may be identified using one or more screening assays, such as those described herein. Such molecules may be

25 administered either in an *ex vivo* manner, or in an *in vivo* manner by injection, or by oral delivery, implantation device, or the like. "Test molecule(s)" refers to the molecule(s) that is/are under evaluation for the ability to modulate (*i.e.*, increase or decrease) the activity of a SMC1 β polypeptide. Most commonly, a test molecule will interact directly with a SMC1 β polypeptide. However, it is also contemplated that a test molecule may also modulate

30 SMC1 β polypeptide activity indirectly, such as by affecting SMC1 β gene expression, or by binding to a SMC1 β binding partner (*e.g.*, receptor, co-factor, or ligand). In one embodiment, a test molecule will bind to a SMC1 β polypeptide with an affinity constant of at

least about 10^{-6} M, preferably about 10^{-8} M, more preferably about 10^{-9} M, and even more preferably about 10^{-10} M.

Methods for identifying compounds which interact with SMC1 β polypeptides are encompassed by the present invention. In certain embodiments, an SMC1 β polypeptide is
5 incubated with a test molecule under conditions which permit the interaction of the test molecule with a SMC1 β polypeptide, and the extent of the interaction can be measured. The test molecule(s) can be screened in a substantially purified form or in a crude mixture.

In certain embodiments, a SMC1 β polypeptide agonist or antagonist may be a protein, peptide, carbohydrate, lipid, or small molecular weight molecule which interacts with
10 SMC1 β polypeptide to regulate its expression or activity. Molecules which regulate SMC1 β polypeptide expression or activity include nucleic acids which are complementary to nucleic acid encoding a SMC1 β polypeptide, or are complementary to nucleic acids sequences which direct or control the expression or activity of SMC1 β polypeptide, and which act as anti-sense regulators of expression or activity.

15 Once a set of test molecules has been identified as interacting with a SMC1 β polypeptide, the molecules may be further evaluated for their ability to increase or decrease SMC1 β polypeptide activity. The measurement of the interaction of test molecules with SMC1 β polypeptides may be carried out in several formats, including cell-based binding assays, membrane binding assays, solution-phase assays and immunoassays. In general, test
20 molecules are incubated with a SMC1 β polypeptide for a specified period of time, and SMC1 β polypeptide activity is determined by one or more assays for measuring biological activity.

The interaction of test molecules with SMC1 β polypeptides may also be assayed directly using polyclonal or monoclonal antibodies in an immunoassay.

25 Alternatively, modified forms of SMC1 β polypeptides containing epitope tags as described herein may be used in immunoassays.

In the event that SMC1 β polypeptides display biological activity through an interaction with a binding partner (*e.g.*, a receptor, a ligand or a co-factor), a variety of *in vitro* assays may be used to measure the binding of a SMC1 β polypeptide to the
30 corresponding binding partner (such as a selective binding agent, receptor, ligand, or co-factor). These assays may be used to screen test molecules for their ability to increase or

decrease the rate and/or the extent of binding of a SMC1 β polypeptide to its binding partner. In one assay, a SMC1 β polypeptide is immobilized in the wells of a microtiter plate. Radiolabeled SMC1 β binding partner (for example, iodinated SMC1 β binding partner) and the test molecule(s) can then be added either one at a time (in either order) or simultaneously to the wells. After incubation, the wells can be washed and counted using a scintillation counter, for radioactivity to determine the extent to which the binding partner bound to SMC1 β polypeptide. Typically, the molecules will be tested over a range of concentrations, and a series of control wells lacking one or more elements of the test assays can be used for accuracy in the evaluation of the results. An alternative to this method involves reversing the "positions" of the proteins, *i.e.*, immobilizing SMC1 β binding partner to the microtiter plate wells, incubating with the test molecule and radiolabeled SMC1 β polypeptide, and determining the extent of SMC1 β polypeptide binding. See, for example, Chapter 18, *Current Protocols in Molecular Biology*, Ausubel *et al.*, eds., John Wiley & Sons, New York, NY (1995).

As an alternative to radiolabelling, a SMC1 β polypeptide or its binding partner may be conjugated to biotin and the presence of biotinylated protein can then be detected using streptavidin linked to an enzyme, such as horseradish peroxidase (HRP) or alkaline phosphatase (AP), that can be detected colorimetrically, or by fluorescent tagging of streptavidin. An antibody directed to a SMC1 β polypeptide or to a SMC1 β binding partner and conjugated to biotin may also be used and can be detected after incubation with enzyme-linked streptavidin linked to AP or HRP.

A SMC1 β polypeptide or a SMC1 β like binding partner can also be immobilized by attachment to agarose beads, acrylic beads or other types of such inert solid phase substrates. The substrate-protein complex can be placed in a solution containing the complementary protein and the test compound. After incubation, the beads can be precipitated by centrifugation, and the amount of binding between a SMC1 β polypeptide and its binding partner can be assessed using the methods described herein. Alternatively, the substrate-protein complex can be immobilized in a column, and the test molecule and complementary protein are passed through the column. The formation of a complex between a SMC1 β polypeptide and its binding partner can then be assessed using any of the techniques set forth herein, *i.e.*, radiolabelling, antibody binding or the like.

Another *in vitro* assay that is useful for identifying a test molecule which increases or decreases the formation of a complex between a SMC1 β polypeptide and a SMC1 β binding partner is a surface plasmon resonance detector system such as the BIAcore assay system (Pharmacia, Piscataway, NJ). The BIAcore system may be carried out using the manufacturer's protocol. This assay essentially involves the covalent binding of either SMC1 β polypeptide or a SMC1 β binding partner to a dextran-coated sensor chip which is located in a detector. The test compound and the other complementary protein can then be injected, either simultaneously or sequentially, into the chamber containing the sensor chip. The amount of complementary protein that binds can be assessed based on the change in molecular mass which is physically associated with the dextran-coated side of the sensor chip; the change in molecular mass can be measured by the detector system.

In some cases, it may be desirable to evaluate two or more test compounds together for their ability to increase or decrease the formation of a complex between a SMC1 β polypeptide and a SMC1 β binding partner. In these cases, the assays set forth herein can be readily modified by adding such additional test compound(s) either simultaneous with, or subsequent to, the first test compound. The remainder of the steps in the assay are set forth herein .

In vitro assays such as those described herein may be used advantageously to screen large numbers of compounds for effects on complex formation by SMC1 β polypeptide and SMC1 β binding partner. The assays may be automated to screen compounds generated in phage display, synthetic peptide, and chemical synthesis libraries.

Compounds which increase or decrease the formation of a complex between a SMC1 β polypeptide and a SMC1 β binding partner may also be screened in cell culture using cells and cell lines expressing either SMC1 β polypeptide or SMC1 β binding partner. Cells and cell lines may be obtained from any mammal, but preferably will be from human or other primate, canine, or rodent sources. The binding of a SMC1 β polypeptide to cells expressing SMC1 β binding partner at the surface is evaluated in the presence or absence of test molecules, and the extent of binding may be determined by, for example, flow cytometry using a biotinylated antibody to a SMC1 β binding partner. Cell culture assays can be used advantageously to further evaluate compounds that score positive in protein binding assays described herein.

Cell cultures can also be used to screen the impact of a drug candidate. For example, drug candidates may decrease or increase the expression or activity of the SMC1 β gene. In certain embodiments, the amount of SMC1 β polypeptide that is produced may be measured after exposure of the cell culture to the drug candidate. In certain embodiments, one may detect the actual impact of the drug candidate on the cell culture. For example, the overexpression of a particular gene may have a particular impact on the cell culture. In such cases, one may test a drug candidate's ability to increase or decrease the expression of the gene or its ability to prevent or inhibit a particular impact on the cell culture. In other examples, the production of a particular metabolic product such as a fragment of a polypeptide, may result in, or be associated with, a disease or pathological condition. In such cases, one may test a drug candidate's ability to decrease the production of such a metabolic product in a cell culture.

A yeast two hybrid system (Chien *et al.*, *Proc. Natl. Acad. Sci. USA*, 88:9578-9583, 1991) can be used to identify novel polypeptides that bind to, or interact with, SMC1 β polypeptides. As an example, a yeast-two hybrid bait construct can be generated in a vector (such as the pAS2-1 from Clontech) which encodes a yeast GAL4-DNA binding domain fused to the SMC1 β polynucleotide. This bait construct may be used to screen human cDNA libraries wherein the cDNA library sequences are fused to GAL4 activation domains. Positive interactions will result in the activation of a reporter gene such as β -Gal. Positive clones emerging from the screening may be characterized further to identify interacting proteins.

G. Therapeutic Uses of SMC1 β

Methods for the treatment of infertility and the induction of fertility using SMC1 β pharmaceutical compositions of the invention are within the scope of the present invention. More specifically, methods of the present invention contemplate the use of SMC1 β pharmaceutical compositions in the regulation or dysregulation of gametogenesis, which encompasses the processes of spermatogenesis and oogenesis. To understand how such compositions might affect these processes, it is important to understand some aspects of spermatogenesis and oogenesis as set out below.

1. *Spermatogenesis*

The seminiferous tubules of the testis contain all the germ cells at various stages of maturation and their supporting Sertoli cells, which account for 85-90% of the testicular volume. Sertoli cells are a fixed-population of non-dividing support cells. Sertoli cells rest on the basement membrane of the seminiferous tubules and are linked by tight junctions. These tight junctions coupled with the close approximation of the myoid cells of the peritubular contractile cell layers serve to form the blood-testis barrier. This barrier provides a unique microenvironment that facilitates spermatogenesis and maintains these germ cells in an immunologically privileged location. This isolation is important because spermatozoa are produced during puberty, long after the period of self-recognition by the immune system. If these developing spermatozoa were not immunologically protected, they would be recognized as foreign and attacked by the body's immune system. Sertoli cells appear to be involved with the nourishment of developing germ cells as well as the phagocytosis of damaged cells. Spermatogonia and young spermatocytes are lower down in the basal compartment of the seminiferous tubule, whereas mature spermatocytes and spermatids are sequestered higher up in the adluminal compartment.

Germ cells or spermatogenic cells are arranged in an orderly manner from the basement membrane up to the lumen. Spermatogonia lie directly on the basement membrane, and next in order, progressing up to the lumen, are found the primary spermatocytes, secondary spermatocytes and spermatids. There are 13 different germ cells representing different stages in the developmental process.

Spermatogenesis is a complex process whereby primitive stem cells or spermatogonia, either divide to reproduce themselves for stem cell renewal or they divide to produce daughter cells that will later become spermatocytes. The spermatocytes eventually divide and give rise to mature cell lines that eventually give rise to spermatids. The spermatids then undergo a transformation into a spermatozoa. This transformation includes nuclear condensation, acrosome formation, loss of most of the cytoplasm, development of a tail and arrangement of the mitochondria into the middle piece of the sperm which basically becomes the engine room to power the tail. Groups of germ cells tend to develop and pass through spermatogenesis together; this sequence of developing germ cells is called a generation. Generations of germ cells are basically in the same stage of development. There are six stages of seminiferous epithelium development in the human male. The progression from stage one through stage six constitutes one cycle. In humans the duration of each cycle

is approximately 16 days and 4.6 cycles are required for a mature sperm to develop from early spermatogonia. Therefore, the duration of the entire spermatogenic cycle in humans is 74 days (4.6 cycles X 16 days/cycle = 74 days).

2. *Oogenesis*

5 Ovaries are egg-producing organs that hold between 200,000 and 400,000 follicles (from folliculus, meaning "sack" in Latin). These cellular sacks contain the materials needed to produce ripened eggs, or ova. In mammals, the ovary is the female gonad responsible for the differentiation and release of a mature oocyte for fertilization and successful propagation of the species. Equally important, the ovary is an endocrine organ that
10 produces steroids to allow the development of female secondary sexual characteristics and support pregnancy. The outermost layer covering the ovary consists of germinal epithelium. Directly underneath the germinal epithelium there is a layer of dense connective tissue known as the tunica albuginea. The ovarian follicles, in conjunction with surrounding fibroblasts, collagen and elastic fibers, form the ovarian cortex located under the tunica albuginea. The
15 ovarian medulla contains the blood vessels, lymphatic vessels and the nervus terminals. The formation of a functional ovary depends on three major events taking place during early stages of gonadogenesis: the initiation of meiosis, the formation of follicles and the differentiation of steroid producing cells.

An ovarian follicle is a highly complex unit consisting of distinct cell types.

20 The ovarian follicle is comprised of several layers of somatic cells surrounding a fluid-filled cavity "Antrum" in which the oocyte surrounded by somatic cells is bathed. The fluid found in the antrum is known as follicular fluid. The follicle provides a microenvironment for oocyte growth and it is responsible for the production of hormones. The oocyte and its companion somatic cells comprising the follicular unit maintain close association throughout
25 development from primordial to preovulatory stages. The walls of mature preovulatory follicles consist of membrana granulosa, theca interna and theca externa. Granulosa cells are cells of epithelial origin essential for the growth and survival of the oocyte. Granulosa cells are not a homogeneous tissue but rather specialized subpopulations consisting of the corona radiata, cumulus cells, mural and antral granulosa cells. The cumulus cells are the
30 subpopulation of ovarian granulosa cells that surrounds the oocyte. The cumulus cells in close contact with the oocyte are known as corona radiata. They are in close contact with the oocyte through cytoplasmic extensions across the zona pellucida.

Follicles can be classified as primordial follicles, preantral follicles (primary and secondary follicles), antral and preovulatory follicles. Folliculogenesis is the process responsible for the development of ovulatory follicles and the release of one or more mature oocytes at a fixed interval throughout the reproductive life of a female. Folliculogenesis is resumed after a long quiescent phase and involves sequential subcellular and molecular transformations by various components of the follicle. During postnatal life, ovarian follicles continue to grow, mature and either ovulate or regress. Follicles are recruited continuously until the original store is exhausted.

Oocytes present in the adult ovary develop from a definite number of primordial germ cells (PGC). Primordial germ cells proliferate during migration and have undergone six or more divisions by the time they colonize the future gonad. Once established in the developing ovary, the proliferating PGC begin to differentiate into oogonia. The oogonia are the stem cells that give rise to all the oocytes in the ovary. The population of oogonia goes through a predetermined, species-specific, number of mitotic cycles until the cells enter the prophase of meiosis and become oocytes. The prophase of meiosis is traditionally separated into five sequential stages: leptotene, zygotene, pachytene, diplotene and diakinesis. The leptotene stage is resumed by the end of an active period of pre-meiotic DNA synthesis. At the leptotene stage, each chromosome condense from its interphase conformation to produce a fine discrete thread. Each chromosome has replicated and consists of two sister chromatids. Zygotene starts as soon as the synapsis or intimate pairing of homologous chromosomes is initiated. Each gene is brought in close juxtaposition with its homologous gene on the opposite chromosome. Each chromosome pair is usually called a bivalent, but each homologous chromosome consists of two sister chromatids or tetrad. The cells are said to have entered the pachytene stage of prophase as soon as synapsis is completed. The synaptonemal complexes are structures that hold the two homologous chromatids together. The maternal and paternal chromatids undergo homologous recombination to allow the exchanges or crossovers between two nonsister chromatids. When the oocyte reaches the pachytene stage, it becomes enclosed in a follicle. The diplotene stage starts with the unpairing of homologous chromosomes in each bivalent after the crossovers are completed. The bivalent remains joined by one or more chiasmata (crossover-sites). The chromosomes take a diffused aspect that permits a period of active RNA synthesis. The nucleus of diplotene oocytes is known as germinal vesicle (GV). The oocyte at the GV stage is a diploid cell ($2n$), which has twice the normal amount of DNA since the first meiotic prophase is stopped at diplotene since the early post-natal period. The oocytes

are considered to be in meiotic arrest. Oocytes remain in meiotic arrest for many months or even years. The mammalian ovary has only a finite supply of oocytes.

The oogonia enlarge and initiate meiosis independently of any endocrine stimulation to form primary oocytes. The primary oocyte becomes arrested at the pachytene or dictyate stage of the first meiotic prophase. The oocyte and the follicular cells are interdependent. The oocyte requires the presence of granulosa cells to grow and survive. Pregranulosa cells rest on a delicate basement membrane opposite the stromal cells that give origin to the theca cells.

Primordial follicles are the fundamental developmental unit of the mammalian ovary. The store of primordial follicles is not renewable and serves the entire reproductive life span of the adult. As the follicles and oocytes start to grow, they move deeper into the cortex of the ovary. The follicle grows out through the cortex as the antrum develops and becomes visible on the surface of the ovary. The mechanism of activation of primordial follicles and oocytes remains unknown. The number of primordial follicles is determined during early life and most of them remain in a resting state. Before and throughout the reproductive life of the female a number of these primordial follicles leave the resting state and start to grow. The follicles develop to the antral stage and most of them undergo atresia; however, some of these follicles are rescued to reach the preovulatory stage. The end of the reproductive life occurs when the pool of resting primordial follicles is exhausted.

Other diseases or disorders caused or mediated by undesirable levels of SMC1 β polypeptide are also encompassed within the therapeutic and diagnostic utilities that are part of the invention. Such diseases or disorders include, but are not limited to, infertility (as discussed herein), a pathological condition, and a nondisjunction syndrome. By way of illustration, such undesirable levels of SMC1 β polypeptide include excessively elevated levels and sub-normal levels of SMC1 β .

H. Selective Binding Agents of SMC1 β

The present invention also provides selective binding agents of SMC1 β for the diagnosis and/or treatment of a pathological condition resulting from abnormal levels of SMC1 β . The diagnosis of such a condition comprises determining the presence or amount of expression or activity of the SMC1 β polypeptide in a sample; and comparing the level of said polypeptide in a biological, tissue or cellular sample from either normal subjects or the

subject at an earlier time, wherein susceptibility to a pathological condition is based on the presence or amount of expression or activity of the SMC1 β nucleic acid or polypeptide.

As used herein, the term "selective binding agent" refers to a molecule which has specificity for one or more SMC1 β polypeptides. Suitable selective binding agents include, but are not limited to, antibodies and derivatives thereof, polypeptides, and small molecules. Suitable selective binding agents may be prepared using methods known in the art. An exemplary SMC1 β polypeptide selective binding agent of the present invention is capable of binding a certain portion of the SMC1 β polypeptide thereby inhibiting the binding of the polypeptide to the SMC1 β polypeptide receptor(s).

Selective binding agents such as antibodies and antibody fragments that bind SMC1 β polypeptides are within the scope of the present invention. The antibodies may be polyclonal including monospecific polyclonal, monoclonal (MAbs), recombinant, chimeric, humanized such as CDR-grafted, human, single chain, and/or bispecific, as well as fragments, variants or derivatives thereof. Antibody fragments include those portions of the antibody which bind to an epitope on the SMC1 β polypeptide. Examples of such fragments include Fab and F(ab') fragments generated by enzymatic cleavage of full-length antibodies. Other binding fragments include those generated by recombinant DNA techniques, such as the expression of recombinant plasmids containing nucleic acid sequences encoding antibody variable regions.

Polyclonal antibodies directed toward a SMC1 β polypeptide generally are produced in animals (e.g., rabbits or mice) by means of multiple subcutaneous or intraperitoneal injections of SMC1 β polypeptide and an adjuvant. It may be useful to conjugate a SMC1 β polypeptide to a carrier protein that is immunogenic in the species to be immunized, such as keyhole limpet heocyanin, serum, albumin, bovine thyroglobulin, or soybean trypsin inhibitor. Also, aggregating agents such as alum are used to enhance the immune response. After immunization, the animals are bled and the serum is assayed for anti- SMC1 β polypeptide antibody titer.

Monoclonal antibodies directed toward SMC1 β polypeptide are produced using any method which provides for the production of antibody molecules by continuous cell lines in culture. Examples of suitable methods for preparing monoclonal antibodies include the hybridoma methods of Kohler *et al.* (*Nature*, 256: 495-497, 1975) and the human B-cell hybridoma method (Kozbor *et al.*, *J. Immunol.*, 133: 3001-3005, 1984; Brodeur *et al.*,

Monoclonal Antibody Production Techniques and Applications, pp. 51-63, Marcel Dekker, Inc., New York, 1987). Also provided by the invention are hybridoma cell lines which produce monoclonal antibodies reactive with h2520-40 polypeptides.

5 The anti- SMC1 β antibodies of the invention may be employed in any known assay method, such as competitive binding assays, direct and indirect sandwich assays, and immunoprecipitation assays (Sola, *Monoclonal Antibodies: A Manual of Techniques*, pp. 147-158 (CRC Press, Inc., 1987)) for the detection and quantitation of h2520-40 polypeptides. The antibodies will bind SMC1 β polypeptides with an affinity which is appropriate for the assay method being employed.

10 For diagnostic applications, in certain embodiments, anti- SMC1 β antibodies typically will be labeled with a detectable moiety. The detectable moiety can be any one which is capable of producing, either directly or indirectly, a detectable signal. For example, the detectable moiety may be a radioisotope, such as ^3H , ^{14}C , ^{32}P , ^{35}S , or ^{125}I , a fluorescent or chemiluminescent compound, such as fluorescein isothiocyanate, rhodamine, or luciferin; or
15 an enzyme, such as alkaline phosphatase, b-galactosidase, or horseradish peroxidase (Bayer *et al.*, *Meth. Enz.*, 184: 138-163, 1990).

 Competitive binding assays rely on the ability of a labeled standard (e.g., a SMC1 β polypeptide, or an immunologically reactive portion thereof) to compete with the test sample analyte (a SMC1 β polypeptide) for binding with a limited amount of anti- SMC1 β
20 antibody. The amount of a SMC1 β polypeptide in the test sample is inversely proportional to the amount of standard that becomes bound to the antibodies. To facilitate determining the amount of standard that becomes bound, the antibodies typically are insolubilized before or after the competition, so that the standard and analyte that are bound to the antibodies may conveniently be separated from the standard and analyte which remain unbound.

25 Sandwich assays typically involve the use of two antibodies, each capable of binding to a different immunogenic portion, or epitope, of the protein to be detected and/or quantitated. In a sandwich assay, the test sample analyte is typically bound by a first antibody which is immobilized on a solid support, and thereafter a second antibody binds to the analyte, thus forming an insoluble three-part complex. See, e.g., U.S. Patent No. 4,376,110.
30 The second antibody may itself be labeled with a detectable moiety (direct sandwich assays) or may be measured using an anti-immunoglobulin antibody that is labeled with a detectable

moiety (indirect sandwich assays). For example, one type of sandwich assay is an enzyme-linked immunosorbent assay (ELISA), in which case the detectable moiety is an enzyme.

The selective binding agents, including anti- SMC1 β antibodies, are also useful for *in vivo* imaging. An antibody labeled with a detectable moiety may be administered to an animal, preferably into the bloodstream, and the presence and location of the labeled antibody in the host is assayed. The antibody may be labeled with any moiety that is detectable in an animal, whether by nuclear magnetic resonance, radiology, or other detection means known in the art.

Selective binding agents of the invention, including anti- SMC1 β antibodies, may be used as therapeutics. These therapeutic agents are generally agonists or antagonists, in that they either enhance or reduce, respectively, at least one of the biological activities of a SMC1 β polypeptide. In one embodiment, antagonist antibodies of the invention are antibodies or binding fragments thereof which are capable of specifically binding to a SMC1 β polypeptide and which are capable of inhibiting or eliminating the functional activity of a SMC1 β polypeptide *in vivo* or *in vitro*. In preferred embodiments, the selective binding agent, *e.g.*, an antagonist antibody will inhibit the functional activity of a SMC1 β polypeptide by at least about 50%, and preferably by at least about 80%. In another embodiment, the selective binding agent may be an antibody that is capable of interacting with a SMC1 β binding partner (a ligand, co-factor, or receptor) thereby inhibiting or eliminating SMC1 β activity *in vitro* or *in vivo*. Selective binding agents, including agonist and antagonist anti-SMC1 β antibodies are identified by screening assays which are well known in the art.

The invention also contemplates to a kit comprising SMC1 β selective binding agents (such as antibodies) and other reagents useful for detecting SMC1 β levels in biological samples. Such reagents may include a secondary activity, a detectable label, blocking serum, positive and negative control samples, and detection reagents.

I. Pharmaceutical Compositions and Administration

Pharmaceutical compositions are within the scope of the present invention. Such SMC1 β pharmaceutical compositions may comprise a therapeutically effective amount of a SMC1 β polypeptide or an SMC1 β nucleic acid molecule in admixture with a

pharmaceutically or physiologically acceptable formulation agent selected for suitability with the mode of administration. Likewise, they may also comprise a contraceptively effective amount of one or more SMC1 β selective binding agents in admixture with a pharmaceutically or physiologically acceptable formulation agent selected for suitability with the mode of administration. Such compositions may be administered in therapeutically or contraceptively effective amounts depending on the application.

Acceptable formulation materials preferably are nontoxic to recipients at the dosages and concentrations employed.

The pharmaceutical composition may contain formulation materials for modifying, maintaining or preserving, for example, the pH, osmolarity, viscosity, clarity, color, isotonicity, odor, sterility, stability, rate of dissolution or release, adsorption or penetration of the composition. Suitable formulation materials include, but are not limited to, amino acids (such as glycine, glutamine, asparagine, arginine or lysine); antimicrobials; antioxidants (such as ascorbic acid, sodium sulfite or sodium hydrogen-sulfite); buffers (such as borate, bicarbonate, Tris-HCl, citrates, phosphates, other organic acids); bulking agents (such as mannitol or glycine), chelating agents (such as ethylenediamine tetraacetic acid (EDTA)); complexing agents (such as caffeine, polyvinylpyrrolidone, beta-cyclodextrin or hydroxypropyl-beta-cyclodextrin); fillers; monosaccharides; disaccharides and other carbohydrates (such as glucose, mannose, or dextrans); proteins (such as serum albumin, gelatin or immunoglobulins); coloring; flavoring and diluting agents; emulsifying agents; hydrophilic polymers (such as polyvinylpyrrolidone); low molecular weight polypeptides; salt-forming counterions (such as sodium); preservatives (such as benzalkonium chloride, benzoic acid, salicylic acid, thimerosal, phenethyl alcohol, methylparaben, propylparaben, chlorhexidine, sorbic acid or hydrogen peroxide); solvents (such as glycerin, propylene glycol or polyethylene glycol); sugar alcohols (such as mannitol or sorbitol); suspending agents; surfactants or wetting agents (such as pluronics, PEG, sorbitan esters, polysorbates such as polysorbate 20, polysorbate 80, triton, tromethamine, lecithin, cholesterol, tyloxapal); stability enhancing agents (sucrose or sorbitol); tonicity enhancing agents (such as alkali metal halides (preferably sodium or potassium chloride, mannitol sorbitol)); delivery vehicles; diluents; excipients and/or pharmaceutical adjuvants. (*Remington's Pharmaceutical Sciences*, 18th Edition, A.R. Gennaro, ed., Mack Publishing Company, 1990).

The optimal pharmaceutical composition will be determined by one skilled in the art depending upon, for example, the intended route of administration, delivery format,

and desired dosage. See for example, Remington's Pharmaceutical Sciences, *supra*. Such compositions may influence the physical state, stability, rate of *in vivo* release, and rate of *in vivo* clearance of the SMC1 β molecule.

5 The primary vehicle or carrier in a pharmaceutical composition may be either aqueous or non-aqueous in nature. For example, a suitable vehicle or carrier may be water for injection, physiological saline solution or artificial cerebrospinal fluid, possibly supplemented with other materials common in compositions for parenteral administration. Neutral buffered saline or saline mixed with serum albumin are further exemplary vehicles. Other exemplary pharmaceutical compositions comprise Tris buffer of about pH 7.0-8.5, or acetate buffer of
10 about pH 4.0-5.5, which may further include sorbitol or a suitable substitute therefor. In one embodiment of the present invention, SMC1 β polypeptide compositions may be prepared for storage by mixing the selected composition having the desired degree of purity with optional formulation agents (*Remington's Pharmaceutical Sciences, supra*) in the form of a lyophilized cake or an aqueous solution. Further, the SMC1 β polypeptide product may be
15 formulated as a lyophilizate using appropriate excipients such as sucrose.

The SMC1 β pharmaceutical compositions can be selected for parenteral delivery. Alternatively, the compositions may be selected for inhalation or for delivery through the digestive tract, such as orally. The preparation of such pharmaceutically acceptable compositions is within the skill of the art.

20 The formulation components are present in concentrations that are acceptable to the site of administration. For example, buffers are used to maintain the composition at physiological pH or at slightly lower pH, typically within a pH range of from about 5 to about 8.

When parenteral administration is contemplated, the therapeutic compositions
25 for use in this invention may be in the form of a pyrogen-free, parenterally acceptable aqueous solution comprising the desired SMC1 β molecule in a pharmaceutically acceptable vehicle. A particularly suitable vehicle for parenteral injection is sterile distilled water in which a SMC1 β molecule is formulated as a sterile, isotonic solution, properly preserved. Yet another preparation can involve the formulation of the desired molecule with an agent,
30 such as injectable microspheres, bio-erodible particles, polymeric compounds (polylactic acid, polyglycolic acid), beads, or liposomes, that provides for the controlled or sustained release of the product which may then be delivered via a depot injection. Hyaluronic acid

may also be used, and this may have the effect of promoting sustained duration in the circulation. Other suitable means for the introduction of the desired molecule include implantable drug delivery devices.

In one embodiment, a pharmaceutical composition may be formulated for inhalation. For example, a SMC1 β like molecule may be formulated as a dry powder for inhalation. SMC1 β polypeptide or SMC1 β nucleic acid molecule inhalation solutions may also be formulated with a propellant for aerosol delivery. In yet another embodiment, solutions may be nebulized. Pulmonary administration is further described in PCT Application No. PCT/US94/001875, which describes pulmonary delivery of chemically modified proteins.

It is also contemplated that certain formulations may be administered orally. In one embodiment of the present invention, SMC1 β molecules which are administered in this fashion can be formulated with or without those carriers customarily used in the compounding of solid dosage forms such as tablets and capsules. For example, a capsule may be designed to release the active portion of the formulation at the point in the gastrointestinal tract when bioavailability is maximized and pre-systemic degradation is minimized. Additional agents can be included to facilitate absorption of the SMC1 β molecule. Diluents, flavorings, low melting point waxes, vegetable oils, lubricants, suspending agents, tablet disintegrating agents, and binders may also be employed.

Another pharmaceutical composition may involve an effective quantity of SMC1 β molecules in a mixture with non-toxic excipients which are suitable for the manufacture of tablets. By dissolving the tablets in sterile water, or other appropriate vehicle, solutions can be prepared in unit dose form. Suitable excipients include, but are not limited to, inert diluents, such as calcium carbonate, sodium carbonate or bicarbonate, lactose, or calcium phosphate; or binding agents, such as starch, gelatin, or acacia; or lubricating agents such as magnesium stearate, stearic acid, or talc.

Additional SMC1 β pharmaceutical compositions will be evident to those skilled in the art, including formulations involving SMC1 β polypeptides in sustained- or controlled-delivery formulations. Techniques for formulating a variety of other sustained- or controlled-delivery means, such as liposome carriers, bio-erodible microparticles or porous beads and depot injections, are also known to those skilled in the art. See for example, PCT/US93/00829 which describes controlled release of porous polymeric microparticles for

the delivery of pharmaceutical compositions. Additional examples of sustained-release preparations include semipermeable polymer matrices in the form of shaped articles, *e.g.* films, or microcapsules. Sustained release matrices may include polyesters, hydrogels, polylactides (U.S. 3,773,919, EP 58,481), copolymers of L-glutamic acid and gamma ethyl-L-glutamate (Sidman *et al.*, *Biopolymers*, 22:547-556, 1983), poly (2-hydroxyethyl-methacrylate) (Langer *et al.*, *J. Biomed. Mater. Res.*, 15:167-277, 1981; Langer *et al.*, *Chem. Tech.* 12:98-105, 1982), ethylene vinyl acetate (Langer *et al.*, *supra*) or poly-D(-)-3-hydroxybutyric acid (EP 133,988). Sustained-release compositions also include liposomes, which can be prepared by any of several methods known in the art. *See e.g.*, Eppstein *et al.*,
5
10 *Proc. Natl. Acad. Sci. USA*, 82:3688-3692, 1985; EP 36,676; EP 88,046; EP 143,949.

The SMC1 β pharmaceutical composition to be used for *in vivo* administration typically must be sterile. This may be accomplished by filtration through sterile filtration membranes. Where the composition is lyophilized, sterilization using this method may be conducted either prior to or following lyophilization and reconstitution. The composition for
15 parenteral administration may be stored in lyophilized form or in solution. In addition, parenteral compositions generally are placed into a container having a sterile access port, for example, an intravenous solution bag or vial having a stopper pierceable by a hypodermic injection needle.

Once the pharmaceutical composition has been formulated, it may be stored in
20 sterile vials as a solution, suspension, gel, emulsion, solid, or a dehydrated or lyophilized powder. Such formulations may be stored either in a ready-to-use form or in a form (*e.g.*, lyophilized) requiring reconstitution prior to administration.

In a specific embodiment, the present invention is directed to kits for producing a single-dose administration unit. The kits may each contain both a first container
25 having a dried protein and a second container having an aqueous formulation. Also included within the scope of this invention are kits containing single and multi-chambered pre-filled syringes (*e.g.*, liquid syringes and lyosyringes).

An effective amount of a SMC1 β pharmaceutical composition to be employed therapeutically including, but not limited to, the treatment of infertility or the induction of
30 infertility will depend, for example, upon the therapeutic context and objectives. One skilled in the art will appreciate that the appropriate dosage levels for treatment will thus vary depending, in part, upon the molecule delivered, the indication for which the SMC1 β

molecule is being used, the route of administration, and the size (body weight, body surface or organ size) and condition (the age and general health) of the patient. Accordingly, the clinician may titer the dosage and modify the route of administration to obtain the optimal therapeutic effect. A typical dosage may range from about 0.01 μ g/kg to up to about 100 mg/kg or more, depending on the factors mentioned above. In other embodiments, the dosage may range from 0.1mg/kg up to about 100 mg/kg; or 1mg/kg up to about 100mg/kg; or 5mg/kg up to about 100 mg/kg.

The frequency of dosing will depend upon the pharmacokinetic parameters of the SMC1 β molecule in the formulation used. Typically, a clinician will administer the composition until a dosage is reached that achieves the desired effect. The composition may therefore be administered as a single dose, or as two or more doses (which may or may not contain the same amount of the desired molecule) over time, or as a continuous infusion via implantation device or catheter. Further refinement of the appropriate dosage is routinely made by those of ordinary skill in the art and is within the ambit of tasks routinely performed by them. Appropriate dosages may be ascertained through use of appropriate dose-response data.

The route of administration of the pharmaceutical composition is in accord with known methods, *e.g.* orally, through injection by intravenous, intraperitoneal, intracerebral (intra-parenchymal), intracerebroventricular, intramuscular, intra-ocular, intraarterial, intraportal, or intralesional routes, by sustained release systems or by implantation devices. Where desired, the compositions may be administered by bolus injection or continuously by infusion, or by implantation device.

Alternatively or additionally, the composition may be administered locally via implantation of a membrane, sponge, or another appropriate material on to which the desired molecule has been absorbed or encapsulated. Where an implantation device is used, the device may be implanted into any suitable tissue or organ, and delivery of the desired molecule may be via diffusion, timed-release bolus, or continuous administration.

In some cases, it may be desirable to use SMC1 β pharmaceutical compositions in an *ex vivo* manner. In such instances, cells, tissues, or organs that have been removed from the patient are exposed to SMC1 β pharmaceutical compositions after which the cells, tissues and/or organs are subsequently implanted back into the patient.

In other cases, a SMC1 β polypeptide can be delivered by implanting certain cells that have been genetically engineered, using methods such as those described herein, to express and secrete the polypeptide. Such cells may be animal or human cells, and may be autologous, heterologous, or xenogeneic. Optionally, the cells may be immortalized. In order to decrease the chance of an immunological response, the cells may be encapsulated to avoid infiltration of surrounding tissues. The encapsulation materials are typically biocompatible, semi-permeable polymeric enclosures or membranes that allow the release of the protein product(s) but prevent the destruction of the cells by the patient's immune system or by other detrimental factors from the surrounding tissues.

J. Gene Therapy

Additional embodiments of the present invention relate to cells and methods (e.g., homologous recombination and/or other recombinant production methods) for both the *in vitro* production of therapeutic polypeptides and for the production and delivery of therapeutic polypeptides by gene therapy or cell therapy. Homologous and other recombination methods may be used to modify a cell that contains a normally transcriptionally silent SMC1 β gene, or an under expressed gene, and thereby produce a cell which expresses therapeutically efficacious amounts of SMC1 β polypeptides.

Homologous recombination is a technique originally developed for targeting genes to induce or correct mutations in transcriptionally active genes (Kucherlapati, *Prog. Nucleic Acid Res. Mol. Biol.* 36:301-310, 1989). The basic technique was developed as a method for introducing specific mutations into specific regions of the mammalian genome (Thomas *et al.*, *Cell* 44:419-428, 1986; Thomas *et al.*, *Cell* 51:503-512, 1987; Doetschman *et al.*, *Proc. Natl. Acad. Sci. USA*, 85:8583-8587, 1988) or to correct specific mutations within defective genes (Doetschman *et al.*, *Nature* 330:576-578, 1987). Exemplary homologous recombination techniques are described in U.S. Patent No. 5,272,071 (EP 9193051, EP Publication No. 505500; PCT/US90/07642, International Publication No. WO 91/09955).

Through homologous recombination, the DNA sequence to be inserted into the genome can be directed to a specific region of the gene of interest by attaching it to targeting DNA. The targeting DNA is a nucleotide sequence that is complementary (homologous) to a region of the genomic DNA. Small pieces of targeting DNA that are complementary to a specific region of the genome are put in contact with the parental strand during the DNA

replication process. It is a general property of DNA that has been inserted into a cell to hybridize, and therefore, recombine with other pieces of endogenous DNA through shared homologous regions. If this complementary strand is attached to an oligonucleotide that contains a mutation or a different sequence or an additional nucleotide, it too is incorporated
5 into the newly synthesized strand as a result of the recombination. As a result of the proofreading function, it is possible for the new sequence of DNA to serve as the template. Thus, the transferred DNA is incorporated into the genome.

Attached to these pieces of targeting DNA are regions of DNA which may interact with or control the expression of a SMC1 β polypeptide, *e.g.*, flanking sequences. For
10 example, a promoter/enhancer element, a suppressor, or an exogenous transcription modulatory element is inserted in the genome of the intended host cell in proximity and orientation sufficient to influence the transcription of DNA encoding the desired SMC1 β polypeptide. The control element controls a portion of the DNA present in the host cell genome. Thus, the expression of the desired SMC1 β polypeptide may be achieved, not by
15 transfection of DNA that encodes the SMC1 β gene itself, but rather by the use of targeting DNA (containing regions of homology with the endogenous gene of interest) coupled with DNA regulatory segments that provide the endogenous gene sequence with recognizable signals for transcription of a SMC1 β polypeptide.

In an exemplary method, the expression of a desired targeted gene in a cell
20 (*i.e.*, a desired endogenous cellular gene) is altered via homologous recombination into the cellular genome at a preselected site, by the introduction of DNA which includes at least a regulatory sequence, an exon and a splice donor site. These components are introduced into the chromosomal (genomic) DNA in such a manner that this, in effect, results in the production of a new transcription unit (in which the regulatory sequence, the exon and the
25 splice donor site present in the DNA construct are operatively linked to the endogenous gene). As a result of the introduction of these components into the chromosomal DNA, the expression of the desired endogenous gene is altered.

Altered gene expression, as described herein, encompasses activating (or causing to be expressed) a gene which is normally silent (unexpressed) in the cell as obtained,
30 as well as increasing the expression of a gene which is not expressed at physiologically significant levels in the cell as obtained. The embodiments further encompass changing the pattern of regulation or induction such that it is different from the pattern of regulation or

induction that occurs in the cell as obtained, and reducing (including eliminating) the expression of a gene which is expressed in the cell as obtained.

One method by which homologous recombination can be used to increase, or cause, SMC1 β polypeptide production from a cell's endogenous SMC1 β gene involves first using homologous recombination to place a recombination sequence from a site-specific recombination system (e.g., Cre/loxP, FLP/FRT) (Sauer *et al.*, *Current Opinion In Biotechnology* 5:521-527, 1994; Sauer *et al.*, *Methods In Enzymology* 225:890-900, 1993) upstream (that is, 5' to) of the cell's endogenous genomic SMC1 β polypeptide coding region. A plasmid containing a recombination site homologous to the site that was placed just upstream of the genomic SMC1 β polypeptide coding region is introduced into the modified cell line along with the appropriate recombinase enzyme. This recombinase causes the plasmid to integrate, via the plasmid's recombination site, into the recombination site located just upstream of the genomic SMC1 β polypeptide coding region in the cell line (Baubonis *et al.*, *Nucleic Acids Res.* 21:2025-2029, 1993; O'Gorman *et al.*, *Science* 251:1351-1355, 1991). Any flanking sequences known to increase transcription (e.g., enhancer/promoter, intron, translational enhancer), if properly positioned in this plasmid, would integrate in such a manner as to create a new or modified transcriptional unit resulting in de novo or increased SMC1 β polypeptide production from the cell's endogenous SMC1 β gene.

A further method to use the cell line in which the site specific recombination sequence had been placed just upstream of the cell's endogenous genomic SMC1 β polypeptide coding region is to use homologous recombination to introduce a second recombination site elsewhere in the cell line's genome. The appropriate recombinase enzyme is then introduced into the two-recombination-site cell line, causing a recombination event (deletion, inversion, translocation) (Sauer *et al.*, *Current Opinion In Biotechnology*, *supra*, 1994; Sauer, *Methods In Enzymology*, *supra*, 1993) that would create a new or modified transcriptional unit resulting in de novo or increased SMC1 β polypeptide production from the cell's endogenous SMC1 β gene.

An additional approach for increasing, or causing, the expression of SMC1 β polypeptide from a cell's endogenous SMC1 β gene involves increasing, or causing, the expression of a gene or genes (e.g., transcription factors) and/or decreasing the expression of a gene or genes (e.g., transcriptional repressors) in a manner which results in de novo or increased SMC1 β polypeptide production from the cell's endogenous SMC1 β gene. This

method includes the introduction of a non-naturally occurring polypeptide (*e.g.*, a polypeptide comprising a site specific DNA binding domain fused to a transcriptional factor domain) into the cell such that *de novo* or increased SMC1 β polypeptide production from the cell's endogenous SMC1 β gene results.

5 The present invention further relates to DNA constructs useful in the method of altering expression of a target gene. In certain embodiments, the exemplary DNA constructs comprise: (a) one or more targeting sequences; (b) a regulatory sequence; (c) an exon; and (d) an unpaired splice-donor site. The targeting sequence in the DNA construct directs the integration of elements (a)-(d) into a target gene in a cell such that the elements
10 (b)-(d) are operatively linked to sequences of the endogenous target gene. In another embodiment, the DNA constructs comprise: (a) one or more targeting sequences, (b) a regulatory sequence, (c) an exon, (d) a splice-donor site, (e) an intron, and (f) a splice-acceptor site, wherein the targeting sequence directs the integration of elements (a)-(f) such that the elements of (b)-(f) are operatively linked to the endogenous gene. The targeting
15 sequence is homologous to the preselected site in the cellular chromosomal DNA with which homologous recombination is to occur. In the construct, the exon is generally 3' of the regulatory sequence and the splice-donor site is 3' of the exon.

 If the sequence of a particular gene is known, such as the nucleic acid sequence of SMC1 β polypeptide presented herein, a piece of DNA that is complementary to a
20 selected region of the gene can be synthesized or otherwise obtained, such as by appropriate restriction of the native DNA at specific recognition sites bounding the region of interest. This piece serves as a targeting sequence(s) upon insertion into the cell and will hybridize to its homologous region within the genome. If this hybridization occurs during DNA replication, this piece of DNA, and any additional sequence attached thereto, will act as an
25 Okazaki fragment and will be incorporated into the newly synthesized daughter strand of DNA. The present invention, therefore, includes nucleotides encoding a SMC1 β polypeptide, which nucleotides may be used as targeting sequences.

 SMC1 β polypeptide cell therapy, *e.g.*, the implantation of cells producing SMC1 β polypeptides, is also contemplated. This embodiment involves implanting cells
30 capable of synthesizing and secreting a biologically active form of SMC1 β polypeptide. Such SMC1 β polypeptide-producing cells can be cells that are natural producers of SMC1 β polypeptides or may be recombinant cells whose ability to produce SMC1 β polypeptides has

been augmented by transformation with a gene encoding the desired SMC1 β polypeptide or with a gene augmenting the expression of SMC1 β polypeptide. Such a modification may be accomplished by means of a vector suitable for delivering the gene as well as promoting its expression and secretion. In order to minimize a potential immunological reaction in patients being administered a SMC1 β polypeptide, as may occur with the administration of a polypeptide of a foreign species, it is preferred that the natural cells producing SMC1 β polypeptide be of human origin and produce human SMC1 β polypeptide. Likewise, it is preferred that the recombinant cells producing SMC1 β polypeptide be transformed with an expression vector containing a gene encoding a human SMC1 β polypeptide.

Implanted cells may be encapsulated to avoid the infiltration of surrounding tissue. Human or non-human animal cells may be implanted in patients in biocompatible, semipermeable polymeric enclosures or membranes that allow the release of SMC1 β polypeptide, but prevent the destruction of the cells by the patient's immune system or by other detrimental factors from the surrounding tissue. Alternatively, the patient's own cells, transformed to produce SMC1 β polypeptides *ex vivo*, may be implanted directly into the patient without such encapsulation.

Techniques for the encapsulation of living cells are known in the art, and the preparation of the encapsulated cells and their implantation in patients may be routinely accomplished. For example, Baetge *et al.* (WO95/05452; PCT/US94/09299) describe membrane capsules containing genetically engineered cells for the effective delivery of biologically active molecules. The capsules are biocompatible and are easily retrievable. The capsules encapsulate cells transfected with recombinant DNA molecules comprising DNA sequences coding for biologically active molecules operatively linked to promoters that are not subject to down-regulation *in vivo* upon implantation into a mammalian host. The devices provide for delivery of the molecules from living cells to specific sites within a recipient. In addition, see U.S. Patent Nos. 4,892,538, 5,011,472, and 5,106,627. A system for encapsulating living cells is described in PCT Application no. PCT/US91/00157 of Aebischer *et al.* See also, PCT Application No. PCT/US91/00155 of Aebischer *et al.*, Winn *et al.*, *Exper. Neurol.* 113: 322-329, 1991, Aebischer *et al.*, *Exper. Neurol.* 111:269-275, 1991; and Tresco *et al.*, *ASAIO* 38:17-23, 1992.

In vivo and *in vitro* gene therapy delivery of SMC1 β polypeptides is also envisioned. One example of a gene therapy technique is to use the SMC1 β gene (either

genomic DNA, cDNA, and/or synthetic DNA) encoding a SMC1 β polypeptide which may be operably linked to a constitutive or inducible promoter to form a "gene therapy DNA construct". The promoter may be homologous or heterologous to the endogenous SMC1 β gene, provided that it is active in the cell or tissue type into which the construct will be inserted. Other components of the gene therapy DNA construct may optionally include, DNA molecules designed for site-specific integration (*e.g.*, endogenous sequences useful for homologous recombination), tissue-specific promoter, enhancer(s) or silencer(s), DNA molecules capable of providing a selective advantage over the parent cell, DNA molecules useful as labels to identify transformed cells, negative selection systems, cell specific binding agents (as, for example, for cell targeting), cell-specific internalization factors, and transcription factors to enhance expression by a vector as well as factors to enable vector manufacture.

A gene therapy DNA construct can then be introduced into cells (either *ex vivo* or *in vivo*) using viral or non-viral vectors. One means for introducing the gene therapy DNA construct is by means of viral vectors as described herein. Certain vectors, such as retroviral vectors, will deliver the DNA construct to the chromosomal DNA of the cells, and the gene can integrate into the chromosomal DNA. Other vectors will function as episomes, and the gene therapy DNA construct will remain in the cytoplasm.

In yet other embodiments, regulatory elements can be included for the controlled expression of the SMC1 β gene in the target cell. Such elements are turned on in response to an appropriate effector. In this way, a therapeutic polypeptide can be expressed when desired. One conventional control means involves the use of small molecule dimerizers or rapalogs (as described in WO9641865 (PCT/US96/099486); WO9731898 (PCT/US97/03137) and WO9731899 (PCT/US95/03157) used to dimerize chimeric proteins which contain a small molecule-binding domain and a domain capable of initiating biological process, such as a DNA-binding protein or transcriptional activation protein. The dimerization of the proteins can be used to initiate transcription of the transgene.

An alternative regulation technology uses a method of storing proteins expressed from the gene of interest inside the cell as an aggregate or cluster. The gene of interest is expressed as a fusion protein that includes a conditional aggregation domain which results in the retention of the aggregated protein in the endoplasmic reticulum. The stored proteins are stable and inactive inside the cell. The proteins can be released, however, by administering a drug (*e.g.*, small molecule ligand) that removes the conditional aggregation

domain and thereby specifically breaks apart the aggregates or clusters so that the proteins may be secreted from the cell. See, *Science* 287:816-817, and 826-830 (2000).

Other suitable control means or gene switches include, but are not limited to, the following systems. Mifepristone (RU486) is used as a progesterone antagonist. The
5 binding of a modified progesterone receptor ligand-binding domain to the progesterone antagonist activates transcription by forming a dimer of two transcription factors which then pass into the nucleus to bind DNA. The ligand-binding domain is modified to eliminate the ability of the receptor to bind to the natural ligand. The modified steroid hormone receptor system is further described in U.S. 5,364,791; WO9640911; and WO9710337.

10 Yet another control system uses ecdysone (a fruit fly steroid hormone) which binds to and activates an ecdysone receptor (cytoplasmic receptor). The receptor then translocates to the nucleus to bind a specific DNA response element (promoter from ecdysone-responsive gene). The ecdysone receptor includes a transactivation domain/DNA-binding domain/ligand-binding domain to initiate transcription. The ecdysone system is
15 further described in U.S. 5,514,578; WO9738117; WO9637609; and WO9303162.

Another control means uses a positive tetracycline-controllable transactivator. This system involves a mutated tet repressor protein DNA-binding domain (mutated tet R-4 amino acid changes which resulted in a reverse tetracycline-regulated transactivator protein, i.e., it binds to a tet operator in the presence of tetracycline) linked to a polypeptide which
20 activates transcription. Such systems are described in U.S. Patent Nos. 5,464,758; 5,650,298 and 5,654,168.

Additional expression control systems and nucleic acid constructs are described in U.S. Patent Nos. 5,741,679 and 5,834,186, to Innovir Laboratories Inc.

In vivo gene therapy may be accomplished by introducing the gene encoding a
25 SMC1 β polypeptide into cells via local injection of a SMC1 β nucleic acid molecule or by other appropriate viral or non-viral delivery vectors. (Hefti, *Neurobiology* 25:1418-1435, 1994). For example, a nucleic acid molecule encoding a SMC1 β polypeptide may be contained in an adeno-associated virus (AAV) vector for delivery to the targeted cells (e.g., Johnson, International Publication No. WO95/34670; International Application No.
30 PCT/US95/07178). The recombinant AAV genome typically contains AAV inverted terminal repeats flanking a DNA sequence encoding a SMC1 β polypeptide operably linked to functional promoter and polyadenylation sequences.

Alternative suitable viral vectors include, but are not limited to, retrovirus, adenovirus, herpes simplex virus, lentivirus, hepatitis virus, parvovirus, papovavirus, poxvirus, alphavirus, coronavirus, rhabdovirus, paramyxovirus, and papilloma virus vectors. U.S. Patent No. 5,672,344 describes an *in vivo* viral-mediated gene transfer system involving a recombinant neurotrophic HSV-1 vector. U.S. Patent No. 5,399,346 provides examples of a process for providing a patient with a therapeutic protein by the delivery of human cells which have been treated *in vitro* to insert a DNA segment encoding a therapeutic protein. Additional methods and materials for the practice of gene therapy techniques are described in U.S. Patent No. 5,631,236 involving adenoviral vectors; U.S. Patent No. 5,672,510 involving retroviral vectors; and U.S. 5,635,399 involving retroviral vectors expressing cytokines.

Nonviral delivery methods include, but are not limited to, liposome-mediated transfer, naked DNA delivery (direct injection), receptor-mediated transfer (ligand-DNA complex), electroporation, calcium phosphate precipitation, and microparticle bombardment (*e.g.*, gene gun). Gene therapy materials and methods may also include the use of inducible promoters, tissue-specific enhancer-promoters, DNA sequences designed for site-specific integration, DNA sequences capable of providing a selective advantage over the parent cell, labels to identify transformed cells, negative selection systems and expression control systems (safety measures), cell-specific binding agents (for cell targeting), cell-specific internalization factors, and transcription factors to enhance expression by a vector as well as methods of vector manufacture. Such additional methods and materials for the practice of gene therapy techniques are described in U.S. Patent No. 4,970,154 involving electroporation techniques; WO96/40958 involving nuclear ligands; U.S. Patent No. 5,679,559 describing a lipoprotein-containing system for gene delivery; U.S. Patent No. 5,676,954 involving liposome carriers; U.S. Patent No. 5,593,875 concerning methods for calcium phosphate transfection; and U.S. Patent No. 4,945,050 wherein biologically active particles are propelled at cells at a speed whereby the particles penetrate the surface of the cells and become incorporated into the interior of the cells.

It is also contemplated that SMC1 β gene therapy or cell therapy can further include the delivery of one or more additional polypeptide(s) in the same or a different cell(s). Such cells may be separately introduced into the patient, or the cells may be contained in a single implantable device, such as the encapsulating membrane described above, or the cells may be separately modified by means of viral vectors.

A means to increase endogenous SMC1 β polypeptide expression in a cell via gene therapy is to insert one or more enhancer element(s) into the SMC1 β polypeptide promoter, where the enhancer element(s) can serve to increase transcriptional activity of the SMC1 β gene. The enhancer element(s) used will be selected based on the tissue in which one desires to activate the gene(s); enhancer elements known to confer promoter activation in that tissue will be selected. For example, if a gene encoding a SMC1 β polypeptide is to be “turned on” in T-cells, the lck promoter enhancer element may be used. Here, the functional portion of the transcriptional element to be added may be inserted into a fragment of DNA containing the SMC1 β polypeptide promoter (and optionally, inserted into a vector and/or 5' and/or 3' flanking sequence(s), etc.) using standard cloning techniques. This construct, known as a “homologous recombination construct”, can then be introduced into the desired cells either *ex vivo* or *in vivo*.

Gene therapy also can be used to decrease SMC1 β polypeptide expression by modifying the nucleotide sequence of the endogenous promoter(s). Such modification is typically accomplished via homologous recombination methods. For example, a DNA molecule containing all or a portion of the promoter of the SMC1 β gene(s) selected for inactivation can be engineered to remove and/or replace pieces of the promoter that regulate transcription. For example the TATA box and/or the binding site of a transcriptional activator of the promoter may be deleted using standard molecular biology techniques; such deletion can inhibit promoter activity thereby repressing the transcription of the corresponding SMC1 β gene. The deletion of the TATA box or the transcription activator binding site in the promoter may be accomplished by generating a DNA construct comprising all or the relevant portion of the SMC1 β polypeptide promoter(s) (from the same or a related species as the SMC1 β gene(s) to be regulated) in which one or more of the TATA box and/or transcriptional activator binding site nucleotides are mutated via substitution, deletion and/or insertion of one or more nucleotides. As a result, the TATA box and/or activator binding site has decreased activity or is rendered completely inactive. The construct will typically contain at least about 500 bases of DNA that correspond to the native (endogenous) 5' and 3' DNA sequences adjacent to the promoter segment that has been modified. The construct may be introduced into the appropriate cells (either *ex vivo* or *in vivo*) either directly or via a viral vector as described herein. Typically, the integration of the construct into the genomic DNA of the cells will be via homologous recombination, where the 5' and 3' DNA sequences in the

promoter construct can serve to help integrate the modified promoter region via hybridization to the endogenous chromosomal DNA.

K. Diagnostic Methods

5 The present invention encompasses methods of diagnosing a pathological condition or a susceptibility to a pathological condition in a subject caused by or resulting from abnormal levels of SMC1 β nucleic acid or polypeptide. In particular, this aspect of the invention provides a method of diagnosing such a condition comprising determining the presence or amount of expression or activity of the SMC1 β polypeptide in a sample; and
10 comparing the level of said polypeptide in a biological, tissue or cellular sample from either normal subjects or the subject at an earlier time, wherein susceptibility to a pathological condition is based on the presence or amount of expression or activity of the SMC1 β nucleic acid or polypeptide.

 The present invention further provides methods of diagnosing abnormal levels
15 of SMC1 β by providing a tissue sample from a person, and determining the loss or mutation of a SMC1 β encoding nucleic acid in the cells of said tissue. In particular, this aspect of the invention provides a method of diagnosing such abnormal levels by nucleic acid hybridization.

 Suitable hybridization conditions for the diagnostic methods are those
20 conditions that allow the detection of gene expression from identifiable expression units such as genes. Preferred hybridization conditions are stringent hybridization conditions, such as hybridization at 42°C in a solution (i.e., a hybridization solution) comprising 50% formamide, 1% SDS, 1 M NaCl, 10% dextran sulfate, and washing twice for 30 minutes at 60°C in a wash solution comprising 0.1 X SSC and 1% SDS. It is understood in the art that conditions
25 of equivalent stringency can be achieved through variation of temperature and buffer, or salt concentration, as described in Ausubel, et al. (Eds.), *Protocols in Molecular Biology*, John Wiley & Sons (1994), pp. 6.0.3 to 6.4.10. Modifications in hybridization conditions can be empirically determined or precisely calculated based on the length and the percentage of guanosine/cytosine (GC) base pairing of the probe. The hybridization conditions can be
30 calculated as described in Sambrook, et al., (Eds.), *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press: Cold Spring Harbor, New York (1989), pp. 9.47 to 9.51.

The sequence of the SMC1 β cDNA can be used to generate probes to detect chromosome abnormalities in the SMC1 β . These probes may be generated from both the sense and antisense strands of double-stranded DNA. The term "SMC1 β probe" refers to both genomic and cDNA probes derived from the SMC1 β gene.

5 cDNA probes capable of detecting mutations in the SMC1 β gene are particularly preferred. Part or all of the SMC1 β cDNA sequence may be used to create a probe capable of detecting aberrant transcripts of SMC1 β .

Using the probes of the present invention, several methods are available for detecting chromosome abnormalities in the SMC1 β gene. Such methods include, for
10 example, Polymerase Chain Reaction (PCR) technology, restriction fragment length analysis, and oligonucleotide hybridization using, for example, Southern and Northern blotting and in situ hybridization.

PCR technology is practiced routinely by those having ordinary skill in the art and its uses in diagnostics are well known and accepted. Methods for practicing PCR
15 technology are disclosed in PCR Protocols: A Guide to Methods and Applications, Innis, M.A. et al., Eds., Academic Press, San Diego, Calif. 1990, and RT-PCR, Clontech Laboratories (1991), which are incorporated herein by reference. Applications of PCR technology are disclosed in Polymerase Chain Reaction, Erlich, H A. et al., Eds., Cold Spring Harbor Press, Cold Spring Harbor, N.Y. 1989, which is incorporated herein by reference.

20 PCR technology allows for the rapid generation of multiple copies of DNA sequences by providing 5' and 3' primers that hybridize to sequences present in a DNA molecule, and further providing free nucleotides and an enzyme which fills in the complementary bases to the DNA sequence between the primers with the free nucleotides to produce a complementary strand of DNA. The enzyme will fill in the complementary
25 sequences between probes only if both the 5' primer and 3' primer hybridize to DNA sequences on the same strand of DNA.

Antisense oligonucleotides which hybridize to at least a portion of an aberrant transcript resulting from a mutation of the SMC1 β gene are also contemplated by the present invention. The oligonucleotide may match the target region exactly or may contain several
30 mismatches. Thus, molecules which bind competitively to RNA coded by, for example, the SMC1 β gene, for example, are envisioned for therapeutics.

The term "oligonucleotide" as used herein includes both ribonucleotides and deoxyribonucleotides, and includes molecules which may be long enough to be termed "polynucleotides." Oligodeoxyribonucleotides are preferred since oligoribonucleotides are more susceptible to enzymatic attack by ribonucleotides than deoxyribonucleotides. It will also be understood that the bases, sugars or internucleotide linkages may be chemically modified by methods known in the art. Modifications may be made, for example, to improve stability and/or lipid solubility. For instance, it is known that enhanced lipid solubility and/or resistance to nuclease digestion results by substituting a methyl group or sulfur atom for a phosphate oxygen in the internucleotide phosphodiester linkage. The phosphorothioates, in particular, are stable to nuclease cleavage and soluble in lipid. Modified oligonucleotides are termed "derivatives."

The oligonucleotides of the present invention may be synthesized by any of the known chemical oligonucleotide synthesis methods. See for example, Gait, M.J., ed. (1984), *Oligonucleotide Synthesis* (IRL, Oxford). In certain embodiments, 10 or more oligonucleotide probes may be arrayed in the form of a diagnostic chip or "microarray" for the analysis and expression of these genes in various cell types. Such a microarray could be used for measuring gene expression of SMC1 β and preferably comprises distinct sequences derived from wild-type and mutant SMC1 β .

L. Examples

The following examples present preferred embodiments and techniques, but are not intended to be limiting. Those of skill in the art will, in light of the present disclosure, appreciate that many changes can be made in the specific materials and methods which are disclosed and still obtain a like or similar result without departing from the spirit and scope of the invention.

Example 1 Control of SMC1 β Expression

To determine the transcription start site for the SMC1 β gene, primer extension of mRNA is carried out as described by Ausubel et al. *John Wiley and Sons, Inc.* (2003). For full characterization of the 5' region of SMC1 β , the start site for the gene (GENBANK Accession No. AK016311) that originates somewhere around the first exon of SMC1 β and is

transcribed in reverse orientation is determined. For primer annealing, total RNA either from mouse testis or liver (control tissue which does not express SMC1 β) is used. Both transcripts are relatively abundant as they can be easily detected by Northern blotting. Therefore, primer extension products are abundant enough to be detected directly in the denaturing polyacrylamide gel.

Information on the position of transcription start sites allow for selection of DNA fragments for electrophoretic mobility shift assay described below. If the transcription start sites of the two genes are far apart, for example, if the start site for the gene (GENBANK Accession No. AK016311) is located within the SMC1 β coding sequence, subsequent studies would concentrate on the region surrounding the SMC1 β transcription start site. If the start sites are close to each other, both are analyzed simultaneously. The GC-rich sequence between the two genes can cause reverse transcriptase to pause or terminate prematurely. Then products of intermediate size are visible in the gel. To prevent such artifacts, it may be necessary to move the positions of the primers closer to the transcription start, so that the extension products are shorter than 100 nucleotides. High nucleotide concentration and elevated reaction temperature support an efficient reaction. As a positive control, the primer extension reaction with a primer for an unrelated testis-specific mRNA with a known transcription start site is used, for example, the germ-cell specific transcription factor, ALF (TFIIA α /beta-like factor; Xie *et al*, *J. Biol. Chem.* 277:17765-74, 2002).

To confirm the mapping results with a second approach, RNase protection assay is used as described (Ausubel *et al.*, 2003). For this assay a commercially available kit (RiboQuant RPA kit, Pharmingen) is used. A series of probes specific for SMC1 β upstream region are generated, and a probe for ribosomal protein L32 mRNA is used as a positive control. Samples of total RNA from testes and liver (negative control) are tested.

The same controls as used for primer extension assays are used, i.e. usage of RNA from mitotic cells, or analyzing a different meiosis-specific gene.

Example 2

Specific Protein Binding to the Promotor Region

To test specific binding of protein(s) to the promotor region, electrophoretic mobility shift assays (EMSA) are carried out with overlapping double-stranded synthetic oligonucleotides, approximately 30-35 bp long and spanning the region identified as a

potential promoter by computer analysis. Oligonucleotides are designed to incorporate potential transcription factor binding sites detected by computer analysis. EMSA is performed according to published protocols (Akhmedov *et al.*, *J. Biol. Chem.* 273:24088-24094, 1998 and Akhmedov *et al.*, *J. Biol. Chem.* 274:38216-38224, 1999). To identify factors specific
5 for spermatogenesis, nuclear extracts, prepared either from mouse testis or liver, are used (Jessberger *et al.*, *Mol. Cell. Biol.* 11:445-457, 1991; Jessberger *et al.*, *Journ. Biol. Chem.* 26:15070-15079, 1993; Jessberger *et al.*, *Journ. Biol. Chem.* 270:6788-6797, 1995; Jessberger *et al.*, *EMBO-J.* 15:4061-4068, 1996; Borggreffe *et al.*, *J. Biol. Chem.* 273:17025-17035, 1998).

10 If testis-specific binding products are undetectable with any of the probes, it may indicate that proteins potentially binding the diagnostic sequences are present in a relatively low concentration. This could happen, for example, if a transcription factor is specific for a certain stage of meiosis, of which only relatively few cells are present in the total testis. To enrich nuclear extracts for stage-specific proteins, extracts are prepared from
15 spermatocytes isolated by cell elutriation as described (Clifton *et al.*, *J. of Endocrin* 172:565-574, 2002; Borggreffe *et al.*, *J. Biol. Chem.* 273:17025-17035, 1998) or the StaPut gradient method (Lam *et al.*, *Proc Natl Acad Sci USA* 65:192-199, 1970).

To confirm binding specificity, competition experiments are performed. Unlabeled specific or non-specific and unrelated double-stranded oligonucleotides are used as
20 competitors. If the sequence of oligonucleotides that bind testis-specific factor(s) corresponds to a consensus sequence for a known transcription factor, point mutations will be designed by the SequenceShaper program (Genomatix, Munich, GERMANY). This program predicts point mutations which delete defined binding sites without generating a new site or affecting other sites. Resulting oligonucleotides are used in competition experiments. For previously
25 unknown binding sites, sets of random mutations are generated. To localize binding sites more precisely, DNase I footprinting analysis is performed as described (Choi and Chae, *J. Biol. Chem.* 266:20504-20511, 1991).

The data obtained by EMSA, supplemented by DNase I footprinting, provide the rationale for isolation of regulatory proteins by DNA affinity chromatography and for
30 designing mutants to be tested *in vivo*.

Example 3

DNA Affinity Chromatography

Sequences within the SMC1 β 5' region that binds a testis-specific factor as seen in EMSA and DNase footprinting assays are used for purification of that binding activity from testis nuclear extracts. Standard DNA affinity chromatography, and an alternative method, oligonucleotide trapping (Gadgil and Jarret, *J Chromatogr. A* 966:99-110, 2002), which is a modification of DNA affinity chromatography are used. For standard affinity chromatography, the double-stranded oligonucleotide is linked via an amino group coupled to one end to CNBr-sepharose beads. Nuclear extracts are loaded under conditions similar to the ones used in the EMSA experiments, and bound proteins are eluted with increasing salt concentration. In the alternative method, a column-attached single stranded oligonucleotide (AC)₅ is used to trap from the solution a double-stranded footprint oligonucleotide with single stranded (TG)₅ overhangs. First, the interaction between the binding protein and the footprint oligonucleotide is carried out in solution. The protein-DNA complex is then passed over an (AC)₅-Sepharose column where (TG)₅ overhangs anneal with high specificity to (AC)₅. The proteins can be eluted from the column by high salt. This method permits protein binding at low DNA concentrations, therefore possibly reducing non-specific binding. Several competitors like heparin, single-stranded non-specific oligonucleotides, or non-specific double-stranded DNA, can be used to further reduce non-specific protein binding. For an additional control, nuclear extracts from mitotic cells or tissue are used. The specifically eluted proteins are separated on an SDS polyacryamide gel and identified by microsequencing and/or mass spectrometry at the proteomics core facility at Mt. Sinai.

Example 4

Promoter Analysis with Reporter Genes

To analyze the SMC1 β promoter activity *in vivo*, constructs containing the wildtype SMC1 β promoter/enhancer region, its subfragments, or its mutated variants, fused to a reporter gene are generated. Point mutations in putative regulatory factor binding sites are introduced by PCR using mutagenic primers, and the products are entirely sequenced (Sequencing core facility, Mt. Sinai). A 21-kbp BAC clone, subcloned 6 kbp, and sequenced 2100 bp has been obtained. Within that sequence a promoter region has been theoretically identified, but enhancers may be located at an even further distance.

To determine the role of the predefined promoter sequences in SMC1 β expression in spermatocytes, transgenic mice and/or a new spermatogonial cell culture system (Feng *et al.*, *Science* 297:392-395, 2002) are used. For generation of transgenic mice, the expression constructs are injected by the Mt. Sinai Mouse Genetics Shared Facility.

- 5 Verification of transgenic animals is performed by Southern analysis of tail DNA. At least two founders with different transgene insertion sites, and preferably a single copy of the transgene for each construct are selected. Transfection of spermatogonial cells and their subsequent release into meiosis is described below. Because the SMC1 β promoter may be bidirectional, constructs with promoter elements in both orientations in respect to the reporter
10 are made after having defined the critical regions.

- The bacterial β -galactosidase (*lacZ*) gene is used as a reporter to allow for the analysis of transgene expression *in situ* in testis sections. This is done by a procedure allowing good conservation of the seminiferous epithelium structure as described by Sage *et al.*, *Mech. Dev.* 80:29-39 (1999). Briefly, testes are fixed in paraformaldehyde and incubated in
15 X-gal solution for staining. After staining, the tissue is fixed in paraformaldehyde, embedded into a resin, and sections are made. For identification of cell types, sections are counterstained with hematoxylin(Mt. Sinai Histology Core Facility). Concentrations of paraformaldehyde and X-gal and duration of incubations are optimized if necessary.

- Thus, the meiotic stage at which the transgene is expressed is determined by
20 identification of the specific cell associations. Expression of the transgene is quantified by measuring β -galactosidase activity by a standard enzymatic assay and photometric read-out in cell extracts (Shaper *et al.*, *J Biol Chem.* 269:25165-25171, 1994). This allows for the determination of tissue specificity of expression. A disadvantage of using *lacZ* as a reporter gene for the analysis of testis-specific expression is the presence of relatively high β -
25 galactosidase activity in testis extracts (Shaper *et al.*, *J Biol Chem.* 269:25165-25171, 1994). Nevertheless, *lacZ* has been successfully used as a reporter in studies of the activity of *Hsp70-2* and *Sycp1* promoter regions during spermatogenesis in transgenic mice (Dix *et al.*, *Dev. Biol.* 174:310-321, 1996; Sage *et al.*, *Mech. Dev.* 80:29-39, 1999). Alternatively, chloramphenicol acetyltransferase (CAT) or the luciferase activity assay are also used if the
30 SMC1 β promoter or its fragments confer a low level of transgene expression. Vectors containing CAT, the luciferase reporter gene, *lacZ*, and control vectors are all commercially available. CAT activity or luciferase activity is measured with commercial CAT enzyme assay systems or luciferase assay systems according to the manufacturer's protocols. In all

experiments analyzing gene/enzyme expression in testes, corresponding control assays using somatic organs are included.

An additional way to analyze the specific stage of meiosis at which SMC1 β regulatory elements become active is by comparing reporter protein activity in testis extracts from mice at different ages. The first wave of meiosis in male mice occurs at the stage of leptotene spermatocytes, which appears at about day 10 after birth. Pachytene cells appear at day 14. The activity of the reporter gene in juvenile mice testes is assayed between days 8 to 21 after birth.

Example 5 Methylation Patterns of CpG Sites in the SMC1 β Promoter Region

The stretch of DNA 200 bp upstream of the SMC1 β start codon contains 24 CpG sites. Initial evaluation of methylation pattern of this region is done by digestion of the genomic DNA extracted from the testis and liver of adult mice with restriction endonucleases sensitive to methylation. Digested DNA is analyzed by Southern blotting with probes spanning the promoter region. Methylation-sensitive restriction endonucleases, *Bst*UI, *Hha*I, and *Hpa*II, are used, for example. The restriction endonuclease, *Msp*I, is used as a control because it recognizes the same site as *Hpa*II, but is insensitive to methylation. There are four *Bst*UI sites, five *Hha*I sites, and one *Hpa*II site located within the stretch of DNA 200 bp upstream of the SMC1 β start codon. A probe for mitochondrial DNA, which is not methylated, is also used to verify that the digestion was complete.

To obtain data on the exact methylation pattern of the promoter region and to evaluate the degree of methylation for each CpG site, the bisulfite method (Clark *et al.*, *Nucleic Acids Res* 22:2990-2997, 1994). is used. Purified genomic DNA from somatic tissues and testes are treated with sodium bisulfite to convert the unmethylated cytosines to uracil residues. The treatment leaves methylated cytosines unaffected. The SMC1 β promoter region is subsequently amplified by PCR with specific primers, and the products are cloned and sequenced. If the conversion by bisulfite is complete, all cytosine residues in the sequence will represent the cytosines methylated in the genome. As a control for complete conversion of unmethylated cytosines, plasmid DNA containing the promoter region is mixed with genomic DNA, treated with bisulfite, amplified with vector specific primers, and sequenced. A modification of the bisulfite method by Olek *et al.* *Nucleic Acids Res.* 24:5064-

5066 (1996) allows the resolution of methylation patterns using genomic DNA from less than 100 individual cells. It is useful to examine methylation of the SMC1 β promoter in testicular cells at different stages of spermatogenesis. Germ cell populations are isolated by StaPut method as described (Lam *et al*, *Proc Natl Acad Sci USA* 65:192-199, 1970). Testes from
5 immature mice are used to evaluate the methylation status of the promoter in spermatogonia.

To determine if methylation patterns of the SMC1 β promoter differ in somatic and spermatogenic cells, a series of experiments are performed to examine if methylation affects SMC1 β promoter activity. First, to determine if demethylation of the promoter activates transcription, cultured cells of established lines (for example, 293 cells, which do not
10 have any detectable SMC1 β transcription) or mouse embryonic fibroblasts are treated with 5-Aza-2'-deoxycytidine, non-methylatable cytosine analog, and transcription of SMC1 β are assessed by RT-PCR. If transcription of SMC1 β depends on demethylation, the non-methylated promoter constructs introduced into cultured cells by plasmid transfection will be transcriptionally active. If that is the case, plasmids are methylated *in vitro* by treatment with
15 *Sss*I methylase, and the gene activity of methylated and non-methylated constructs is then compared. If non-methylated promoter constructs are active in cell lines, they are used in transfection experiments to analyze the effects of deletions and point mutations. It is then determined if the SMC1 β promoter fused to a reporter gene is methylated and silenced after stable integration and propagation in cultured cell lines. To determine if methylation affects
20 binding of testis-specific factors, EMSA experiments with synthetic methylated oligonucleotides as competitors are repeated.

Example 6 Regulation of SMC1 β Function

25 Preliminary data has suggested the involvement of targeted proteolysis in the regulation of SMC1 β function. Such proteolysis is not unprecedented for cohesin proteins (e.g. mitotic Scc1). It is hypothesized that for the proper regulation of SMC1 β function, and therefore of meiotic progression, the protein must be removed from meiotic chromosomes at
30 specific stages and from specific regions of the chromosomes. Because the dissociation is a two-step process as follows: 1) dissociation from the chromosome arms in metaphase I; and 2) dissociation from the centromeres at metaphase II, it must not only be highly controlled, but also be governed by stage- and chromosomal region-specific signals. Two mechanisms of

control used in many biological systems for comparable processes, and for dissociation of mitotic cohesin from mitotic chromosomes, are protein degradation and/or protein phosphorylation.

There is evidence for both protein degradation and protein phosphorylation in the regulation of SMC1 β function. To better understand the role that protein degradation plays in the regulation of SMC1 β , SMC1 β -degrading proteolytic activity assays are being repeated. Indications are that this activity: 1) has a certain specificity for SMC1 β ; 2) depends on ATP; 3) is significantly higher if phosphatases present in the extract are blocked; 4) generates a 120-kDa intermediate; and 5) is inhibited specifically by an N-terminal peptide of SMC1 β . Experiments are also being undertaken to purify the protease that degrades SMC1 β , determine the cleavage site(s) within SMC1 β , define the role of phosphorylation in the cleavage reaction, and purify the respective kinase. In addition, efforts are being made to determine the role of SMC1 β degradation *in vivo*.

Example 7

Protease Purification

Analysis of the amino acid sequence of the inhibitory N-terminal region of SMC1 β revealed a single cleavage site for proline endopeptidase (PEP), and clusters of three cleavage sites for separase. While, PEP may be a rather unlikely enzyme to be responsible for SMC1 β cleavage, PEP's involvement in SMC1 β cleavage is being examined. In fact, both PEP and separase are being tested for a role in the cleavage of SMC1 β . Specific inhibitors are available for both enzymes: Boc-Glu(NHO-Bz)-Pyr (Ki 30 nM inhibit human PEP; Calbiochem Inc.), and non-cleavable peptides inhibit separase (Waizenegger *et al.*, *Cell* 103:399-410, 2000). These inhibitors are useful in cleavage assays *in vitro* containing testis nuclear extracts. These proteases are also being examined using *in vivo* assays.

If inhibition experiments provide indications for a role for either PEP or separase in SMC1 β cleavage, recombinant PEP (purified by standard Ni-column chromatography; Kimura *et al.*, *Zool. Sci.* 19:93-102, 2002), or immunoprecipitated separase (shown to be active; antibodies are available from Dr. J. M. Peters, Vienna), is then used to analyze cleavage of immunoprecipitated SMC1 β . If one or both of the enzymes cleaves the SMC1 β protein, the N-terminal peptide, or a peptide that carries a mutated protease recognition site, is then used as an inhibitor(s) in control experiments. While there are

several sites for each of the enzymes in the full-length SMC1 β , the site which generates the 120-kDa intermediate is being sought. If SMC1 β is rapidly degraded, regardless of inhibitor peptide added, it is assumed that the protease is nonspecific or that specific regulatory mechanisms are missing in the reaction, e.g. cleavage of a phosphorylated SMC1 β . SMC1 β is then prepared from extract treated with phosphatase or phosphatase-inhibitors and/or with ATP. If the N-terminal peptide, but not control peptides, inhibit the reaction, there is either no cleavage or delayed cleavage. However, if inhibition by the N-terminal peptide depends on its phosphorylation, or on co-factors, this system, based on individual purified proteins, will not show the inhibitory effect nor specificity. *Ex vivo* purification experiments are carried out as described herein. Any positive result in cleavage assays, using a recombinant, purified protease, is also verified by *in vivo* experiments discussed herein.

It is also possible that neither one of these two candidate proteases, PEP nor separase, cleaves SMC1 β at the terminal site. If this is determined to be the case, the SMC1 β protease is purified from testis nuclear extracts by a wide variety of established chromatographic and protein separation methods. These methods include gel filtration on various resins like Superdex75 and 200 for lower and medium molecular weight ranges and BioGelA15m and A50m for the high molecular weight ranges. These methods further include ion exchange chromatography on BioRex70, DEAE cellulose, MacroQ, and MacroS resins. They also include mixed affinity-ion exchange chromatography on heparin sepharose and a variety of dye-sepharose resins. Precise details of these chromatography procedures are known to one of skill in the art, and are described in the references cited herein.

Extracts are prepared by salt-extraction of isolated nuclei (Jessberger and Berg, *Mol. Cell. Biol.* 11:445-457, 1991; Jessberger *et al.*, *Journ. Biol. Chem.* 268:15070-15079, 1993, Jessberger *et al.*, *EMBO-J.* 15:4061-4068, 1996; Borggreffe *et al.*, *J. Biol. Chem.* 273:17025-17035, 1998), and as described in initial cleavage assays. The stringency of extraction is varied, for example, either by altering salt concentrations (usually in the range from 0.25 to 0.75 M KCl) or by varying the salt from KCl, to ammonium sulfate, or to NaCl to optimize the starting material. Other parameters during extraction and fractionation are varied to optimize the experiment by one of skill in the art, including the use of reducing or non-reducing buffers, the use of mild detergents, different pH, etc. However, a robust activity has been seen with extracts as prepared, and variations are limited except when necessary or deliberate.

The read-out is as described, i.e. immunoblot analysis of SMC1 β degradation.

Unlike that in total nuclear extracts, there is probably no SMC1 β in more purified protease fractions, the SMC1 β /SMC3 dimer, immunoprecipitated from testis extracts (a highly reproducible, efficient method; see Revenkova *et al.*, *Mol. Cell. Biol.* 21:6984-6998, 2001) is added as a substrate. Preliminary experiments have shown that this substrate is cleaved in testis nuclear extracts (in addition to the endogenous protein). Alternatively, commercially available *in vitro* transcription/translation systems, that by radioactive labeling of SMC1 β with S35-methionine also are used to generate a sensitive read-out, even if only low amounts of this relatively large protein are being synthesized. One potential problem is that perhaps two or more activities need to act together to specifically cleave SMC1 β . Thus, if specific cleavage by just one protein fraction is not seen, fractions, or pools of fractions, are combined and further purified. As a further control, the inhibitory N-terminal fragment is used to ensure purification of the specific protease.

The protease is identified by mass spectrometry (proteomics core facility at Mt. Sinai). Identification of the protease allows for the study of SMC1 β regulation. An *in vitro* system that uses immunoprecipitated SMC1 β and recombinant or *ex vivo* purified protease can then be established to study details the mechanism and regulation of protease cleavage. This allows for better study of the inhibition of the protease or its activation. These cell-free experiments are carried out with the same controls and limitations as discussed herein for the other two candidate proteases. However, this system is more specific and complete, because any necessary co-factor(s) (additional fraction), are simultaneously purified. Experiments are then performed to analyze the role of the protease in meiosis *in vivo*.

Example 8

Identification of the SMC1 β Protease Cleavage Site

In attempts to identify the protease cleavage site within SMC1 β , N-terminal and C-terminal protein fragments of SMC1 β were purified in increasing concentrations of imidazole in elution buffer and run on silver-stained SDS polyacrylamide gels. To assay degradation, increasing amounts of N- or C-terminal protein fragments were then added to a reaction containing extract incubated with and without competitor. Reactions were then separated electrophoretically on SDS polyacrylamide gels, immunoblotted, and probed with anti- SMC1 β antibody. The N-terminal 33-kDa fragment was identified as an inhibitor to

protease cleavage. While this is likely competitive inhibition, it cannot be ruled out that this peptide inhibits a protease through a different mechanism which does not require it to be a generic cleavage substrate. Cleavage of the N-terminal fragment itself is currently being investigated.

5 Based on the hypothesis that the N-terminal region of SMC1 β contains a
cleavage site that is required for the subsequent total degradation of SMC1 β , smaller
fragments of the N-terminal region are being used to determine the size of potential cleavage
products of that fragment, and thus minimize the inhibitory peptide. In analogy to many other
protease cleavage recognition sites, a minimal peptide is expected to be not more than 30
10 amino acids in length. Such peptides can be chemically synthesized, and a variety of mutants
can be made. Failure of such mutants to inhibit the cleavage reaction provides a good
indication of the protease target site.

Having identified such a minimal inhibitory sequence, or even specific amino acids required for inhibition, an SMC1 β protein that is mutated in these sites is then created, either by deleting the entire minimal sequence, or by point mutating the essential amino acids. This mutant SMC1 β is then expressed in an *in vitro* transcription/translation system, and tested by incubation in either an extract that has been depleted for SMC1 β , or in a (semi-)purified protease fraction. The mutant protein is also tested *in vivo* as discussed herein.

20 **Example 9** **The Role of Phosphorylation**

Preliminary results have shown that the presence of phosphatase inhibitors stimulates the cleavage reaction. Therefore, the addition of phosphatase to the reaction may inhibit the cleavage and is being examined. It has also been shown that ATP stimulates SMC1 β degradation. This effect may be explained in several ways, e.g. by activation of the proteasome, which in turn removes a protease inhibitor. However, it may also indicate activation of a kinase present in the testis nuclear extract that would phosphorylate SMC1 β . Preliminary experiments have shown that the N-terminal fragment of SMC1 β is phosphorylated by incubation in the extract with γ - ^{32}P -ATP.

The effect of phosphorylation may be either on SMC1 β – marking it for degradation – or on the protease – activating the enzyme. It may even be indirect, e.g. activating an activator or inhibiting an inhibitor of the protease. Currently, either of these

possibilities cannot be distinguished. However, it is speculated that phosphorylation of SMC1 β is the most likely event that stimulates - or is even required - for its degradation. This hypothesis is based on analogies: analogy with Scc1, another cohesin subunit, that in mitosis becomes targeted for degradation by phosphorylation. This speculation is also based on the reported phosphorylation of SMC1 α , the ubiquitous isoform of SMC1 β , by ATM kinase (Yazdi *et al.*, *Genes Dev.* 16:571-582, 2002; Kim *et al.*, *Genes & Dev.* 16:560-570, 2002); the observation (by ^{32}P -labeling and two-dimensional gel electrophoresis of immunoprecipitated material) of phosphorylation of SMC1 α and SMC3 in mitotic cells; and the observation of phosphorylation of the SMC1 β N-terminal peptide in testis nuclear extracts.

Assuming that a phosphorylated SMC1 β is a target for protein degradation, the identify of the respective kinase in the cleavage reaction is being investigated.

Immunoprecipitated SMC1 β is used as a substrate in standard kinase assays. γ - ^{32}P -ATP is incubated under appropriate buffer conditions with the substrate and a protein fraction.

Products are visualized by autoradiography after SDS gel electrophoresis. Controls include omission of the substrate, use of large numbers of fractions that are negative, and use of unrelated proteins as substrate. Activity is also examined in mitotic cells. However, the kinase does not necessarily have to be meiosis-specific, because, for example, its own activation pathway may be meiosis-specific.

Besides using the full-length SMC1 β , fragments expressed in *E. coli* are also used. In preliminary assays, it has already been determined that the N-terminal, but not the C-terminal fragment is phosphorylated by testis nuclear extracts. This observation is being confirmed in current experiments, but indicates that the N-terminal fragment may be used as a competitive inhibitor or as a substrate for kinase purification (including as an affinity substrate in affinity chromatography) for kinase reactions.

There is no definite answer yet as to why a recombinant, non-phosphorylated N-terminal fragment inhibits the protease reaction, but there are many possibilities. For example, the peptide may just be bound but not cleaved if phosphorylation is required for cleavage. Also, it is possible that the inhibitory effect is seen only because of excess peptide, which is a weak substrate. Likewise, it is possible that phosphorylation is required only for targeting the full-length SMC1 β , not for a small fragment.

Some known kinases may be candidates for phosphorylating SMC1 β . For example, ATM is known to phosphorylate SMC1 α and is also required for meiosis. Furthermore, meiosis in ATM-deficient mice is disrupted at the pachytene stage (Barlow *et al.*, *Development* 125:4007-4017, 1998). Heterozygous ATM-deficient mice are being bred; and chromosome spreads for the distribution of SMC1 β in prophase I cells are being analyzed. A cell line that expresses a tagged ATM protein has also been obtained (from Dr. Y. Shiloh), from which the kinase can be immunoprecipitated and used in kinase assays.

Another candidate kinase is the cyclinA1/Cdc2, which has been shown to be specifically expressed in male germ cells during late prophase I (Ravnik and Wolgemuth, *Dev. Biol.* 207:408-418, 1999). SMC1 β expression in meiotic cells from cyclin A1 deficient mice (provided by Dr. Debra Wolgemuth, Columbia University) is being studied with the use of an anti SMC1 β antibody. Spermatogenesis in these mice has been shown to stop at metaphase I (Liu *et al.*, *Dev Biol.* 224:388-400, 2000).

Having purified a kinase that phosphorylates SMC1 β , the specific phosphorylation site is then determined. If the reaction is highly efficient, direct analysis by mass spectrometry is possible. Alternatively, individual domains of SMC1 β , expressed in *E. coli*, are used as kinase substrates to identify and minimize the region of phosphorylation. The very N-terminus, the protease-inhibitory N-terminal fragment, the hinge domain, the C-terminal fragment used in inhibition experiments, and the very C-terminus have been expressed and purified. Together these fragments account for 86 % of the entire SMC1 β protein. Should the phosphorylation site reside in the remaining sequences, the respective protein region will be expressed and purified. After reducing the phosphorylation region to a few hundred amino acids or less, standard methods, like mass spectrometry or peptide cleavage/thin layer chromatography, are then used to identify the phosphorylated residue(s).

25

Example 10 **Functional Testing with SMC1 β *In Vivo***

Results obtained by molecular approaches are verified in cells and/or animals, including the use of transgenic (random integration) or knock-in mice, SMC1 β ^{-/-} mice (already created and described herein), and the establishment of spermatogonial cell cultures that can be triggered to undergo meiosis (Feng *et al.*, *Science* 97:392-395, 2002).

30

The newly generated SMC1 β ^{-/-} strain provides an ideal model for organismal experiments. This strain serves as a proof-of-concept model, since it is clear that homozygous SMC1 β ^{-/-} mice are viable and live beyond the beginning of the reproductive age (the oldest have now lived past 18 weeks of age). The mice have demonstrated no obvious phenotype beyond a meiotic one. Their testes are smaller and weigh 50 % less than of controls. Additionally, the testes are apparently devoid of meiotic cells. The mice have shown to be sterile as demonstrated by breeding experiments. These mice have proven useful not only for the study of SMC1 β 's role in fertility but also for its role in meiosis. Furthermore, these mice have demonstrated that the elimination of SMC1 β expression or activity is an attractive one for inducing infertility without many or any side effects. Likewise, these mice present an interesting model for the study of infertility.

Knock-in mice that carry a specifically mutated SMC1 β gene at its natural genomic locus are also being created. Techniques and materials required to generate such transgenic animals are well known in the art and have been used in the generation of the SMC1 β ^{-/-} mouse (Borggreffe *et al.*, *Europ. J. Immunol.* 31:2467-2475, 2001). Several modes of regulation of SMC1 β may be examined by this approach. Having identified a protease cleavage and/or a phosphorylation site, a point mutation is created in that site by site-directed mutagenesis (Masat *et al.*, *Proc Natl Acad Sci USA* 97:2180-2184, 2000; Shinohara *et al.*, *Nature* 416:759-763, 2002). The mutant gene is then inserted in place of the wildtype gene. The mice are then analyzed for their meiotic phenotypes, for chromosomal association of SMC1 β , and for SMC1 β complex formation. Failure to dissociate SMC1 β from the chromosomes, either at metaphase I (chromosome arms) or at metaphase II (centromeres), may arrest meiosis. These experiments also reveal whether the specific proteolysis or phosphorylation event(s) is required for arm or centromere dissociation, or both. Similarly, a site specific for a candidate transcription factor that drives the meiosis-specific expression of SMC1 β may be mutated in a knock-in, and the effect of that mutation investigated. If expression of a particular mutant SMC1 β gene has a strong dominant negative phenotype, germline transmission may not occur. Transgenic mice with randomly integrated expression constructs are also contemplated. This approach is particularly attractive for testing meiosis- and tissue-specific expression, e.g. of a promoter/enhancer region. A candidate region is linked to the lacZ gene, whose expression can readily be analyzed.

In a different approach, spermatogonial cell culture system (Feng *et al.*, *Science* 297:392-395, 2002) is utilized. In this system, type A spermatogonial cells are partially purified from mouse testes using the STA-PUT apparatus. Cells are transfected with an expression vector for mTeRT (telomerase reverse transcriptase), which immortalizes them without transformation. Cultures proliferate and remain undifferentiated for a long time period, but can be induced to undergo meiosis by addition of stem cell factor (SCF; kit ligand). After 1 week of induction, 40 % of the cells are reported to be 4N, and after 3 weeks of induction 58 % of the total cell population are haploid. An established spermatogonial wildtype line is also available from Dr. Martin Dym (Georgetown University). Cultures are also being established from SMC1 β ^{-/-} spermatogonial cells (SMC1 β is not expressed before prophase I of meiosis). This cell system allows for numerous experimental approaches. For example, phosphatase (okadaic acid, vanadate) or kinase inhibitors (Wortmannin, staurosporine, or a variety of others) added to the cells at specific steps of meiosis are analyzed for their effects in culture. Likewise, specific protease inhibitors (as described herein for PEP or separase) are also tested. FACS analysis is used to examine meiotic progression (Borggreffe *et al.*, *Europ. J. Immunol.* 29:1812-1822, 1999; Borggreffe *et al.*, *Europ. J. Immunol.* 31:2467-2475, 2001; Stursberg *et al.*, *Gene* 228:1-12, 1999; and Gross *et al.*, *Europ. J. Immunol.* 32:1121-1128, 2002); and immunofluorescence of chromosome spreads. Cell populations, highly enriched for a specific stage of meiosis, are then analyzed for the presence of proteolytic activity. As is common for inhibitor experiments, some conclusions may be limited because some inhibitors are not of high enough specificity (e.g. Wortmannin) or may block a specific enzyme that may be required for other essential cellular functions, causing apoptosis or other effects that may perturb analysis. Thus, inhibitor experiments are only to be interpreted in the context of other results. One such approach is the expression of transgenes in spermatogonial cells.

Because cultured cells can be efficiently transfected with expression constructs of ones choice (Feng *et al.*, *Science* 297:392-395, 2002), wildtype or mutant SMC1 β genes may be expressed to study their effects on meiosis in wildtype cells. This allows for the expression of mutant kinase or protease genes and the analysis of potential dominant negative phenotypes. Wildtype or mutant SMC1 β genes are also being expressed in SMC1 β ^{-/-} cells to try complementing their phenotype and assess the effect of mutants in this background. Thus, this approach allows for the study of interaction and chromosome association, i.e. structure-function data from this approach. The different roles of SMC1 β in meiosis, e.g. in arm

cohesion, centromeric cohesion, and perhaps DNA recombination are also being examined in culture. This system allows for the more rapid study of the effects of interfering with SMC1 β than the animal models do. Both systems, the cell culture and the animal system, are complementary, but not dependent on each other.

5 The expression of small interfering RNA molecules in the spermatogonial cells, as a means to further manipulating SMC1 β function, and a precursor of possible future use of SMC1 β as a drug target is also contemplated in this invention.

10 **Example 11** **SMC1 β 's Role in Meiosis and Fertility**

 The invention also contemplate the role of SMC1 β *in vivo*, and its relevance for human reproductive health. It further opens the possibility for interfering with SMC1 β as a means to very specifically and effectively block meiosis. A protein that is key to meiotic sister chromatid cohesion and likely also to meiotic DNA recombination, is expected to be
15 essential for spermatogenesis and thus male fertility. It is quite possible that it is essential for oogenesis as well, since all female SMC1 β knockout mice have all exhibited infertility. Therefore, it is a useful protein target for the induction of infertility, for example, as a method of contraception, or the treatment of infertility.

20 The only other meiosis-specific cohesins, Rec8 and STAG3, may be less attractive target candidates. Rec8 appears too early, i.e. in the premeiotic division, and STAG3 disappears much earlier than SMC1 β , and likely interacts only with a subset of cohesin complexes in mammalian meiosis. In yeast, defective Rec8 transforms the first meiotic division into a mitotic cycle (Watanabe *et al.*, *Nature* 400:461-464, 2001). The
25 central cohesin SMC1 β is an attractive target also, because the cohesin complexes form a protein structure independent of the synaptonemal complex (Pelttari *et al.*, *Mol. Cell. Biol.* 21:5667-5777, 2001). Thus, one may even envision a multilevel approach that targets the SC proteins and cohesin(s).

 In meiosis, chromosomal missegregation is found in frequent chromosomal
30 nondisjunction syndromes including the trisomies 21 (Down syndrome), 18, 16, and 15 (Nicolaidis and Peterson, *Human Reprod.* 13:313-319, 1998). Correct sister chromatid cohesion and recombination are prerequisites for proper meiotic divisions, and it is plausible to imagine missegregation to happen if, for example, the SMC1 β protein, or factors

associated with it, were defective. Phenotypic results may be the aneuploidy or sterility syndromes, both with clear medical and social implications. In fact, more than 90 % of all cases of trisomy 21 are due to errors in female meiosis, most of them happening in meiosis I. Similar numbers were reported for other trisomies (trisomies 18, 16, 15). Also, about 50 % of spontaneous abortions that occur before 15 weeks of gestation are chromosomally aneuploid with a high incidence of trisomies (Nicolaidis and Peterson, *Human Reprod.* 13:313-319, 1998). Infertility is a very common medical problem that affects about 10 % of couples and has a significant familial component, with autosomal recessive inheritance accounting for half of the male cases (Lilford *et al.*, *BMJ* 309:570-573, 1994). While many genes are probably involved in this complex phenomenon, genes encoding proteins that are key to meiotic chromosome dynamics are among the prime candidates. For example, meiotic arrest at the primary spermatocyte stage may be triggered if sister chromatid cohesion or DNA recombination fail. Such arrest is the most common type of maturation arrest in men with non-obstructive azoospermia (Martin-du Pan and Campana, *Fertil Steril.* 60:937-946, 1993). Indeed, analysis of synaptonemal complex formation in patients revealed extensive synaptic anomalies that could be related to the meiotic arrest seen in these individuals (Egozcue *et al.*, *Mol. Cell. Endocrinol.* 174:310-321, 2000).

While naturally occurring deficiencies in a specific protein like SMC1 β likely cause severe fertility problems, artificially disabling SMC1 β may turn into an advantage for regulating reproduction, i.e. for contraception. Conceptually it is attractive to look for a target that is both, highly important and highly specific for meiosis. SMC1 β fulfills both requirements. Thus, the function of SMC1 β in the organism will be studied and interfered with in order to better understand its potential role in the induction of infertility (as a contraceptive) and in the treatment of infertility. Analyzing the regulation of SMC1 β expression, activity, and function may further help to identify other targets for contraceptive intervention, like meiosis-specific transcription factors or components of specific proteolysis pathways.

Example 12

SMC1 β Toxicity in Somatic Cells

There has been some limited experimental evidence that suggests that SMC1 β may be toxic if expressed in somatic cells. Expression constructs, that allow for inducible

expression, for either the somatic SMC1 α or the meiotic SMC1 β were transfected into 293 cells (a somatic cell line), and stable clones were selected on the basis of neomycin-resistance. While more than 10 clones that stably (long-term) expressed SMC1 α were obtained, no clones were obtained for SMC1 β . Two clones that expressed SMC1 β initially
5 stopped expressing it after a few passages. After the induction of expression, cells appeared to die.

These experiments are being repeated. Additional experiments include the use of transient gene expression, and the resulting phenotypes are being examined for apoptosis and cell cycle arrest. However, if SMC1 β proves to be toxic or detrimental to somatic cells,
10 it would provide the basis for an assay with which to screen compounds or agents that inhibit SMC1 β expression or activity.

It should be understood that the foregoing description relates to preferred embodiments of the invention and equivalents and variations that will be apparent to the
15 reader are also intended as aspects of the invention. The references referred to herein throughout are incorporated by reference.

What is Claimed is:

1. A method for inducing infertility in an animal, comprising administering to an animal an effective contraceptive amount of an agent that inhibits SMC1 β expression or activity.

5 2. The method of claim 1 which further comprises restoring fertility to said animal by ceasing administration of said agent.

3. The method of claim 1, wherein said infertility is caused by blocking spermatogenesis.

10 4. The method of claim 3, wherein said spermatogenesis is blocked by inhibiting meiosis.

5. The method of claim 1, wherein said infertility is caused by blocking oogenesis.

6. The method of claim 5, wherein said oogenesis is blocked by inhibiting meiosis.

15 7. The method of claims 4 or 6, wherein said meiosis is inhibited at prophase of meiosis I or later.

8. The method of any of claims 1 through 7, wherein said agent is selected from the group consisting of: a nucleic acid construct, a small molecule antagonist of SMC1 β , a peptidomimetic antagonist of SMC1 β , and an anti-SMC1 β antibody.

20 9. The method of claim 8, wherein the agent is administered in a composition comprising a pharmaceutically acceptable carrier.

10. The composition of claim 9, wherein the pharmaceutically acceptable carrier is an adjuvant, solubilizer, stabilizer, diluent, anti-oxidant, liposome, micelle, or patch.

25 11. A method of treating infertility in an animal, comprising administering to said animal an effective therapeutic amount of exogenous SMC1 β or an agent that induces SMC1 β expression or activity.

12. The method of claim 11, wherein said infertility is treated by stimulating spermatogenesis.

30 13. The method of claim 12, wherein said spermatogenesis is stimulated by inducing meiosis.

14. The method of claim 11, wherein said infertility is treated by stimulating oogenesis.
15. The method of claim 14, wherein said oogenesis is stimulated by inducing meiosis.
- 5 16. The method of claims 13 or 15, wherein said meiosis is induced at or after prophase of meiosis I.
17. The method of any of claims 11 through 16, wherein said agent is selected from the group consisting of: a nucleic acid construct that encodes the SMC1 β polypeptide, a SMC1 β polypeptide, a small molecule agonist of SMC1 β , and a
10 peptidomimetic agonist of SMC1 β .
18. The method of claim 17, wherein the agent is administered in a composition comprising a pharmaceutically acceptable carrier.
19. The composition of claim 18, wherein the pharmaceutically acceptable carrier is an adjuvant, solubilizer, stabilizer, diluent, anti-oxidant, liposome, micelle, or patch.
- 15 20. The method of claims 9 or 18, wherein the agent is administered orally, parenterally, topically, or transdermally.
21. The method of claims 3 or 12, wherein the administration is to the testis.
22. The method of claim 21, wherein the administration to the testis is by a
20 route selected from the group consisting of: injection, implantation, and transdermal application.
23. The method of claims 5 or 14, wherein the administration is to the ovary.
24. The method of claim 23, wherein the administration is by injection or
25 implantation into the ovary.
25. The method of claims 1 or 11, wherein the animal is human.
26. A method of inhibiting meiosis in germ cells, comprising inhibiting the expression or activity of SMC1 β in said cells.
27. The method of claim 26, wherein said germ cells are spermatocytes.

28. The method of claim 26, wherein said germ cells are oocytes.
29. The method of claim 26, wherein said meiosis is inhibited at prophase
of meiosis I.
30. The method of claim 30, wherein said cells are located in vitro.
- 5 31. The method of claim 30, wherein said cells are located in vivo.
32. The method of claim 30, wherein said cells are located in an animal
subject.
33. The method of claim 32, wherein said subject is human.
34. The method of claim 26, wherein said method comprises contacting
10 said cells with an agent that reduces the expression or activity of SMC1 β .
35. The method of claim 34, wherein said agent is a nucleic acid construct.
36. The method of claim 34, wherein said agent is a small molecule
antagonist of SMC1 β .
37. The method of claim 34, wherein said agent is a peptidomimetic
15 antagonist of SMC1 β .
38. The method of claim 34, wherein said agent is an anti-SMC1 β
antibody.
39. The method of any of claims 34 through 38, wherein the agent is
administered in a composition comprising a pharmaceutically acceptable carrier.
- 20 40. The composition of claim 39, wherein the pharmaceutically acceptable
carrier is an adjuvant, solubilizer, stabilizer, diluent, anti-oxidant, liposome, micelle, or patch.
41. A method of inducing meiosis in germ cells, comprising inducing the
expression or activity of SMC1 β in said cells.
42. The method of claim 41, wherein said germ cells are spermatocytes.
- 25 43. The method of claim 41, wherein said germ cells are oocytes.
44. The method of claim 41, wherein said meiosis is induced at prophase
of meiosis I.
45. The method of claim 45, wherein said cells are located in vitro.

46. The method of claim 45, wherein said cells are located in vivo.
47. The method of claim 45, wherein said cells are located in an animal subject.
48. The method of claim 47, wherein said subject is human.
- 5 49. The method of claim 41, wherein said method comprises contacting said cells with exogenous SMC1 β or an agent that induces the expression or activity of SMC1 β .
50. The method of claim 49, wherein said agent is a nucleic acid construct that encodes the SMC1 β polypeptide.
- 10 51. The method of claim 49, wherein said agent is the SMC1 β polypeptide.
52. The method of claim 49, wherein said agent is a small molecule agonist of SMC1 β .
53. The method of claim 49, wherein said agent is a peptidomimetic agonist of SMC1 β .
- 15 54. The method of any of claims 49 through 53, wherein the agent is administered in a composition comprising a pharmaceutically acceptable carrier.
55. The composition of claim 54, wherein the pharmaceutically acceptable carrier is an adjuvant, solubilizer, stabilizer, diluent, anti-oxidant, liposome, micelle, or patch.
56. A method for treating a disorder in an animal resulting from decreased
20 levels of SMC1 β polypeptide comprising administering to an animal the SMC1 β polypeptide or the nucleic acid encoding the polypeptide of SMC1 β to said animal.
57. A method of diagnosing a disorder or susceptibility to a disorder in an animal caused by or resulting from abnormal levels of SMC1 β polypeptide comprising:
- a) determining the presence or amount of expression or activity of the SMC1 β
25 polypeptide or a nucleic acid encoding the polypeptide of SMC1 β in a sample; and
- b) comparing the level of SMC1 β polypeptide or the nucleic acid encoding the polypeptide of SMC1 β in a biological, tissue, or cellular sample from normal animals or the animal at an earlier time, wherein susceptibility to the disorder is based on the presence or

amount of expression or activity of the SMC1 β polypeptide or the nucleic acid encoding the polypeptide of SMC1 β .

58. The method of claims 56 or 57, wherein the disorder is selected from the group consisting of infertility, a pathological condition, and a nondisjunction syndrome.

5 59. A composition comprising exogenous SMC1 β or an agent that induces SMC1 β expression or activity and a pharmaceutically acceptable carrier.

60. The composition of claim 59, wherein said agent is selected from the group consisting of: a nucleic acid construct that encodes SMC1 β polypeptide, SMC1 β polypeptide, a small molecule agonist of SMC1 β , and a SMC1 β peptidomimetic agonist.

10 61. A composition comprising an agent that reduces SMC1 β expression or activity and a pharmaceutically acceptable carrier.

62. The composition of claim 61, wherein said agent is selected from the group consisting of: a nucleic acid construct that encodes SMC1 β in an antisense orientation, a selective binding agent of SMC1 β polypeptide, a small molecule antagonist of SMC1 β , and
15 a SMC1 β peptidomimetic antagonist.

63. The composition of claims 59 or 61, wherein the pharmaceutically acceptable carrier is an adjuvant, solubilizer, stabilizer, diluent, anti-oxidant, liposome, micelle, or patch.

64. The composition of claim 60, wherein said polynucleotide is contained
20 with a vector.

65. A diagnostic reagent comprising a detectably labeled polynucleotide encoding the SMC1 β polypeptide, or a fragment, variant or homolog thereof.

66. The diagnostic reagent of claim 65, wherein said labeled polynucleotide is a first-strand cDNA.

25 67. A method for detecting the presence of SMC1 β nucleic acids in a biological sample comprising the steps of:

a) providing a biological sample suspected of containing SMC1 β nucleic acids;

b) contacting the biological sample with a diagnostic reagent according to claim 65 under conditions, wherein the diagnostic reagent will hybridize with SMC1 β nucleic acids contained in said biological sample;

5 c) detecting hybridization between SMC1 β nucleic acid in the biological sample and the diagnostic reagent; and

d) comparing the level of hybridization between the biological sample and diagnostic reagent with the level of hybridization between a known concentration of SMC1 β nucleic acid and the diagnostic reagent.

68. A method for detecting the presence of SMC1 β nucleic acids in a
10 tissue or cellular sample comprising the steps of:

a) providing a tissue or cellular sample suspected of containing SMC1 β nucleic acids;

b) contacting the tissue or cellular sample with a diagnostic reagent according to claim 65 under conditions, wherein the diagnostic reagent will hybridize with SMC1 β nucleic
15 acids;

c) detecting hybridization between SMC1 β nucleic acid in the tissue or cellular sample and the diagnostic reagent; and

d) comparing the level of hybridization between the tissue or cellular sample and diagnostic reagent with the level of hybridization between a known concentration of SMC1 β
20 nucleic acid and the diagnostic reagent.

69. The method of claim 67 or 68, wherein said polynucleotide molecule is DNA.

70. The method of claim 67 or 68, wherein said polynucleotide molecule is RNA.

25 71. A method for screening agents that modulate meiosis in germ cells comprising:

a) providing a cell expressing SMC1 β ;

b) contacting said cell with a candidate modulating agent; and

c) monitoring said cell for a change in meiotic activity in the presence and absence of modulating agent; and

wherein an alteration in meiosis indicates that the agent is a meiosis modulating agent.

72. The method of claim 71, wherein said modulating agent increases
5 meiosis.

73. The method of claim 71, wherein said modulating agent decreases
meiosis.

74. The method of claim 71, wherein said cell is a spermatocyte.

75. The method of claim 71, wherein said cell is an oocyte.

10 76. The method of claim 71, wherein said cell is from a transgenic, non-human animal.

77. The method of claim 71, wherein said contacting is performed in vitro.

78. The method of claim 71, wherein said contacting is performed in vivo.

79. The method of claim 71, wherein said candidate modulating agent is a
15 nucleic acid construct that reduces the expression or activity of SMC1 β .

80. The method of claim 71, wherein said candidate modulating agent is a nucleic acid construct that increases the expression or activity of SMC1 β .

81. The method of claim 71, wherein said candidate modulating agent is an antibody of SMC1 β .

20 82. The method of claim 71, wherein said candidate modulating agent is small molecule antagonist of SMC1 β .

83. The method of claim 71, wherein said candidate modulating agent is peptidomimetic antagonist of SMC1 β .

84. A composition comprising a candidate modulating agent of meiosis
25 identified according to the method of any of claims 71 through 83 and a pharmaceutically acceptable carrier.

85. The composition of claim 84, wherein the pharmaceutically acceptable carrier is an adjuvant, solubilizer, stabilizer, diluent, anti-oxidant, liposome, micelle, or patch.

86. A method of modulating levels of SMC1 β in an animal comprising administering to the animal the composition of claim 85.

87. A method of modulating meiosis in an animal comprising administering to the animal the composition of claim 85.

5 88. A method for screening agents that modulate SMC1 β expression or activity in germ cells comprising:

- a) providing a cell expressing SMC1 β ;
 - b) contacting said cell with a candidate modulating agent; and
 - c) monitoring said cell for a change in SMC1 β expression or activity in the
- 10 presence and absence of modulating agent; and

wherein an alteration in SMC1 β expression or activity indicates that the agent is a SMC1 β modulating agent.

89. A method for screening agents that modulate SMC1 β expression or activity in germ cells comprising:

- 15 a) providing somatic cells with an inducible expression construct of SMC1 β ;
- b) contacting said cells with a candidate inhibitor of SMC1 β ; and
- c) monitoring said cells for an increase in proliferation;

wherein an increase in cell proliferation indicates that the agent is a SMC1 β inhibiting agent.

20 90. A composition comprising a candidate modulating agent of meiosis or SMC1 β expression or activity identified according to the method of claims 88 or 89 and a pharmaceutically acceptable carrier.

91. The composition of claim 90, wherein the pharmaceutically acceptable carrier is an adjuvant, solubilizer, stabilizer, diluent, anti-oxidant, liposome, micelle, or patch.

25 92. A method of modulating levels of SMC1 β in an animal comprising administering to the animal the composition of claim 90.

93. A method of modulating meiosis in an animal comprising administering to the animal the composition of claim 90.

94. A transgenic non-human animal whose genome comprises a homozygous null mutation in the endogenous SMC1 β gene, wherein said non-human animal exhibits abnormal development of the germ cells.

95. An isolated cell, or a purified preparation of cells, from a transgenic
5 non-human animal whose genome comprises a homozygous null mutation in the endogenous SMC1 β gene, wherein production of functional SMC1 β is inhibited.

96. The transgenic non-human animal of claim 94 which is a mouse.

97. A method of evaluating a fertility treatment, comprising:

a) administering said treatment to a transgenic mouse whose genome comprises a
10 homozygous null mutation in the endogenous SMC1 β gene, wherein said mouse exhibits abnormal development of the germ cells and is infertile; and

b) determining the effect of the treatment on fertility of said mouse, thereby evaluating said fertility treatment.

98. The method of claim 97, wherein said treatment is evaluated *in vivo*.

15 99. The method of claim 97, wherein said treatment is evaluated *in vitro*.

100. The method of claim 97, wherein the effect of the treatment is determined by sperm count.

101. The method of claim 97, wherein the effect of the treatment is determined by testicular size.

20 102. The method of claim 97, wherein the effect of the treatment is determined by oocyte morphology.

103. The method of claim 97, wherein the effect of the treatment is determined by sperm morphology.

25 104. The method of claim 97, wherein the effect of the treatment is determined by gamete morphology.

105. The method of claim 97, wherein the effect of the treatment is determined by chromosome morphology.

106. The method of claim 97, wherein the effect of the treatment is determined by the ability of chromosomes to pair.

107. The method of claim 97, wherein the effect of the treatment is determined by the ability of the mice to mate and produce offspring.
108. The method of claim 97, wherein the effect of the treatment is determined by the ability of the mice to have normal estrous cycles.
- 5 109. The method of claim 97, wherein the effect of the treatment is determined by ovarian morphology.
110. An expression construct comprising a nucleic acid encoding a SMC1 β polypeptide, fragment, or variant thereof and a heterologous germ cell specific promoter operably linked to said construct.
- 10 111. The construct of claim 110, wherein the nucleic acid is in a sense orientation with respect to the promoter.
112. The construct of claim 110, wherein the nucleic acid is in an antisense orientation with respect to the promoter.
113. The construct of claim 110, which is contained within a viral vector.
- 15 114. The construct of claim 110, wherein said promoter is a testis specific promoter.
115. The construct of claim 114, wherein said promoter is phosphoglycerate kinase 2.
116. The construct of claim 110, wherein said promoter is an oocyte specific
20 promoter.
117. A recombinant host cell, wherein said cell is transformed with the any of the constructs of claims 110 through 116.
118. A composition comprising any of the constructs of claims 110 through 116 and a pharmaceutically acceptable carrier.
- 25 119. The composition of claim 118, wherein the pharmaceutically acceptable carrier is an adjuvant, solubilizer, stabilizer, diluent, anti-oxidant, liposome, micelle, or patch.
120. A device, comprising:
- a) a membrane suitable for implantation; and

b) the composition of claim 118 encapsulated within said membrane, wherein said membrane is permeable to the composition.

121. A device, comprising:

a) a membrane suitable for implantation; and

5 b) the cells of claim 117 encapsulated within said membrane, wherein said cells secrete polypeptide, and wherein said membrane is impermeable to materials detrimental to said cells.

122. The selective binding agent of claims 8, 38, or 81 that is an antibody or a fragment thereof.

10 123. An antibody of fragment thereof that specifically binds SMC1 β polypeptide.

124. The antibody of claim 123 that is a monoclonal antibody.

ABSTRACT

The present invention is directed to methods and compositions for use in the diagnosis and treatment of reproductive fertility. More particularly, it is directed to methods and compositions that can be used in male and female contraception and fertility.

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US04/028240

International filing date: 30 August 2004 (30.08.2004)

Document type: Certified copy of priority document

Document details: Country/Office: US
Number: 60/499,317
Filing date: 29 August 2003 (29.08.2003)

Date of receipt at the International Bureau: 04 October 2004 (04.10.2004)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse